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ABSTRACT 
 
Building and maintaining muscle is critical to the quality of life for adults 
and elderly. Physical activity and nutrition are important factors for long-term 
muscle health. In particular, dietary protein – including protein distribution and 
quality – are under-appreciated determinants of muscle health for adults. The 
most unequivocal evidence for the benefit of optimal dietary protein at individual 
meals is derived from studies of weight management. During the catabolic 
condition of weight loss, higher protein diets attenuate loss of lean tissue and 
partition weight loss to body fat when compared with commonly recommended 
high carbohydrate, low protein diets.   
  Muscle protein turnover is a continuous process in which proteins are 
degraded, and replaced by newly synthesized proteins. Muscle growth occurs 
when protein synthesis exceeds protein degradation. Regulation of protein 
synthesis is complex, with multiple signals influencing this process. The 
mammalian target of rapamycin (mTORC1) pathway has been identified as a 
particularly important regulator of protein synthesis, via stimulation of translation 
initiation. Key regulatory points of translation initiation effected by mTORC1 
include assembly of the eukaryotic initiation factor 4F (eIF4F) complex and 
phosphorylation of the 70 kilodalton ribosomal protein S6 kinase (S6K1). 
Assembly of the eIF4F initiation complex involves phosphorylation of the 
inhibitory eIF4E binding protein-1 (4E-BP1), which releases the initiation factor 
eIF4E and allows it to bind with eIF4G. Binding of eIF4E with eIF4G promotes 
preparation of the mRNA for binding to the 43S pre-initiation complex.  
Consumption of the amino acid leucine (Leu) is a key factor determining 
the anabolic response of muscle protein synthesis (MPS) and mTORC1 signaling 
to a meal. Research from this dissertation demonstrates that the peak activation 
of MPS following a complete meal is proportional to the Leu content of a meal 
and its ability to elevate plasma Leu.  
Leu has also been implicated as an inhibitor of muscle protein degradation 
(MPD). In particular, there is evidence suggesting that in muscle wasting 
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conditions Leu supplementation attenuates expression of the ubiquitin-
proteosome pathway, which is the primary mode of intracellular protein 
degradation. However, this is untested in healthy, physiological feeding models. 
Therefore, an experiment was performed to see if feeding isonitrogenous protein 
sources with different Leu contents to healthy adult rats would differentially 
impact ubiquitin-proteosome (protein degradation) outcomes; and if these 
outcomes are related to the meal responses of plasma Leu. Results showed that 
higher Leu diets were able to attenuate total proteasome content but had no 
effect on ubiquitin proteins.  
This research shows that dietary Leu determines postprandial muscle 
anabolism. In a parallel line of research, the effects of dietary Leu on changes in 
muscle mass overtime were investigated. Animals consuming higher Leu diets 
had larger gastrocnemius muscle weights; furthermore, gastrocnemius muscle 
weights were correlated with postprandial changes in MPS (r=0.471, P<0.01) and 
plasma Leu (r=0.400, P=0.01). These results show that the effect of Leu on 
ubiquitin-proteosome pathways is minimal for healthy adult rats consuming 
adequate diets. Thus, long-term changes in muscle mass observed in adult rats 
are likely due to the differences in MPS, rather than MPD.  
Factors determining the duration of Leu-stimulated MPS were further 
investigated. Despite continued elevations in plasma Leu and associated 
translation initiation factors (e.g., S6K1 and 4E-BP1), MPS returned to basal 
levels ~3 hours after a meal. However, administration of additional nutrients in 
the form of carbohydrate, Leu, or both ~2 hours after a meal was able to extend 
the elevation of MPS, in a time and dose dependent manner. This effect led to a 
novel discovery that decreases in translation elongation activity was associated 
with increases in activity of AMP kinase, a key cellular energy sensor.  
This research shows that the Leu density of dietary protein determines 
anabolic signaling, thereby affecting cellular energetics and body composition. 
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PREFACE 
 
This dissertation attempts to better define the role of dietary leucine (Leu) 
in regulation of skeletal muscle protein balance. While the threshold response of 
mammalian target of rapamycin (mTORC1) and muscle protein synthesis (MPS) 
to plasma Leu concentrations is established from studies using free Leu, the 
significance of this threshold activation in physiological meals with complex 
macronutrient and fiber mixtures is unknown. Accordingly, Chapter II will 
examine the importance of the Leu content of a meal on post-prandial plasma 
Leu concentrations, translation factors 70 kilodalton ribosomal protein S6 kinase 
(S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1), and MPS.  
Much less is known about the regulation of muscle protein degradation 
(MPD). The primary mode of intracellular protein degradation is the ubiquitin-
proteosome pahway. The process of ubiquitination involves covalent attachment 
of ubiquitin – a small, compact, highly conserved polypeptide – to proteins, 
effectively “tagging” them for selective destruction in proteolytic complexes called 
proteasomes. While some studies demonstrate a potential role of Leu in 
regulation of ubiquitin-protoesome signaling, virtually all research has been 
performed in vitro or muscle wasting models and is untested in healthy subjects 
under physiological conditions. Therefore, Chapter III will investigate if feeding 
isonitrogenous protein sources with different Leu contents to healthy adult rats 
will differentially impact key elements of the ubiquitin-proteosome pathway, and if 
changes in the ubiquitin-proteosome pathway relate to meal responses of plasma 
Leu.  
While translation initiation and MPS responses shortly after a meal have 
been well characterized, much less is known about the duration of peak MPS 
following food intake. Therefore, Chapters IV and V will present a series of time-
course experiments designed to determine the duration of muscle protein 
synthesis after a meal, the effects of dietary supplements to extend or enhance 
the duration of protein synthesis, as well as mechanisms ultimately regulating the 
post-meal duration of protein synthesis.  
 xi 
Chapter VI provides a summary of all findings plus thoughts and 
speculations about dietary implications and future research directions.  
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CHAPTER I:  
REVIEW OF LITERATURE 
 
INTRODUCTION 
  This dissertation attempts to better define the role of dietary leucine (Leu) 
in regulation of skeletal muscle protein balance. The purpose of Chapter I is to 
briefly overview current knowledge for this area of research.  
  The primary role of skeletal muscle is control of movement, which 
ultimately underlies both physical and metabolic performance. However, the roles 
of skeletal muscle in metabolic performance and long-term health are rarely 
discussed (71). Increases in muscle metabolic activity may help attenuate 
obesity by raising energy expenditure – through voluntary movement and 
increased muscle protein turnover, an energy costly metabolic process (60).  
  Muscle is a primary tissue for insulin action, is an important site for 
glucose utilization, and provides substrate for hepatic gluconeogensis (33). 
Insulin resistance is reported to originate within skeletal muscle due to inactivity 
and an abundance of cellular energy (28). This metabolic state results in the 
accumulation of intramuscular triglycerides and glucose, resulting in disturbances 
in glucose and insulin metabolism (53). Wolfe (70) demonstrated that fatty acid 
oxidation has minimal direct inhibitory effects on glucose metabolism. 
Conversely, glucose oxidation increases plasma insulin, resulting in decreased 
oxidation and transport of long chain fatty acids into the mitochondria (70). 
Exercise improves insulin sensitivity, in part by increased mitochondrial oxidation 
of glucose and fatty acids (30).  
Building and maintaining muscle is critical to the quality of life for adults 
and elderly, who have a greater risk for muscle loss associated with aging, called 
sarcopenia (71). When an individual’s muscle mass falls more than two standard 
deviations below the sex-specific mean obtained from normative data of 
premenopausal women and men under 50 years of age, the individual is 
determined to have sarcopenia (42). The prevalence of sarcopenia increases 
from 13–24% in persons 50-70 years of age to >50% in persons over 80 years of 
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age (31). Maintenance of muscle mass is a concern in the elderly as its decline is 
associated with a two to three times greater likelihood of functional impairment in 
activities of daily living such as shopping and performing household chores than 
in individuals who fall within a normal range of skeletal muscle tissue (26). The 
most severe consequence of sarcopenia occurs when an individual loses his or 
her capacity to remain functionally independent (21). Research suggests that 
sarcopenia may occur through alterations in protein balance (21, 65, 66).  
  Physical activity and nutrition are important factors for protein balance and 
long-term muscle health. In particular, dietary protein is an underappreciated 
determinant of muscle health for adults. Indeed, decreased quantity and quality 
of protein consumption in the elderly is associated with greater muscle loss and 
increased risk of sarcopenia (29). Conversely, older adults enhance muscle 
strength and size with greater consumption of dietary protein (13). These findings 
call into question the adequacy of current dietary protein recommendations for 
healthy adults (50).  
 
DIETARY PROTEIN GUIDELINES 
  In the United States, protein requirements are based on the 
Recommended Dietary Allowance (RDA) (52) defined as the minimum amount of 
protein to maintain short-term nitrogen balance (0.8g/kg of body weight) using 
data from studies with young adults in ideal health and energy balance (52). 
These guidelines assume that the minimum dietary intake of indispensable or 
essential amino acids (EAA) to optimize nitrogen retention represents the protein 
requirement.  
  The requirement for dietary protein is determined by the proper amounts 
of each of the nine EAA. Hence, both the quantity and quality of proteins is 
important to determining protein requirements.   
  The Protein Digestibility-Corrected Amino Acid Score (PDCAAS) was 
introduced by Food and Agriculture Organization of the World Health 
Organization (FAO/WHO), and is the current international standard for protein 
quality assessment (59). The amino acid score is based on comparison of the 
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concentration of the first limiting essential amino acid in the test protein, with the 
concentration of that amino acid in a reference (scoring) pattern. The amino acid 
score obtained is then corrected for the digestibility of the test protein. The 
current consensus is that meeting the minimum requirements for lysine, 
threonine, methionine, and tryptophan, considered the most limiting amino acids 
in poor quality proteins, determines the amino acid score and will lead to a 
plateau of nitrogen retention (59). At the plateau of nitrogen balance, any further 
increase in plasma amino acids would stimulate increased oxidation and 
elimination of the “excess” amino acids, implying that protein quality above 
requirements does not matter.  
  These criteria are useful for determining the efficiency of protein utilization 
for growth or animal production but fail to reflect the diverse metabolic roles of 
amino acids and long-term health implications. Beyond the fundamental amino 
acid needs for synthesis of new proteins, amino acids participate in numerous 
metabolic roles including cell signaling. In many cases signaling pathways and 
their metabolic outcomes are sensitive to dietary intake. Examples of intracellular 
amino acid concentrations as determinants of cell signaling includes the roles of 
tryptophan as a precursor to the neurotransmitter serotonin, arginine stimulating 
epithelial production of nitrous oxide, and Leu triggering translation initiation of 
protein synthesis (34).   
 
GLOBAL REGULATION OF MUSCLE PROTEIN SYNTHESIS 
  Regulation of protein synthesis is complex, with multiple signals 
influencing this process. First, messenger ribonucleic acid (mRNA) is moved 
from the nucleus to the sarcoplasm where it attaches to ribosomes and the 
accompanying ribosomal proteins. Once mRNA and ribosomes are assembled 
into an active complex, a new protein is constructed, a process known as 
translation. Translation is a three-step process involving initiation, elongation, 
and termination, and is regulated by eukaryotic initiation, elongation, and 
releasing factors, respectively. The initiation process requires multiple proteins 
including at least 12-eukaryotic-initiation factors (eIFs) that direct and facilitate 
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the process. During translation initiation, the mRNA containing the instructions for 
a new protein is assembled to a ribosome. The 40s ribosomal subunit is recruited 
to a selected mRNA and joined with the large 60s ribosome, forming a 80s 
ribosome competent to identify the translation start codon and begin elongation. 
Subsequently, transfer RNA (tRNA) brings individual amino acids to the 
ribosome, where they are linked one after another (translation elongation). 
Finally, translation is terminated when recognition of a stop codon causes 
disassociation of the ribosomal subunits from the mRNA (translation termination).  
  The mammalian target of rapamycin (mTORC1) is a protein complex 
identified as a particularly important regulator of translation. Key regulatory 
proteins for translation initiation effected by mTORC1 include assembly of the 
eukaryotic initiation factor 4F (eIF4F) complex and phosphorylation of the 70 
kilodalton ribosomal protein S6 kinase (S6K1). Assembly of the eIF4F initiation 
complex involves phosphorylation of the inhibitory eIF4E binding protein-1 (4E-
BP1), which releases the initiation factor eIF4E and allows it to bind with eIF4G. 
Binding of eIF4E with eIF4G promotes preparation of the mRNA for the binding 
to the 43S pre-initiation complex.   
  mTORC1 also increases translation elongation by activating the 
eukaryotic elongation factor 2 (eEF2) (11). eEF2 mediates ribosomal 
translocation, and is inhibited by phosphorylation at Thr56, catalyzed by eEF2 
kinase (eEF2K) (54). eEF2K activity is dependent on its ability to bind to Ca2+ 
ions and calmodulin (CaM); while phosphorylation of eEF2K by protein kinases 
affects its ability to bind to CaM. mTORC1 inhibits eEF2K activity by 
phosphorylation of Ser366 (mediated by S6K1) (67), and Ser78, through a yet 
unidentified protein kinase (10).  
  Regulation of mTORC1 is not fully understood but is influenced by multiple 
regulatory proteins, including the tuberous sclerosis complex (TSC1 and TSC2) 
and Ras homolog enriched in brain (Rheb) (45). Rheb, a Ras-like GTPase, is an 
activator of mTORC1 in vivo. The action of Rheb is opposed by the TSC1/TSC2 
complex, which acts as a Rheb GTPase, promoting the conversion of Rheb-GTP 
to Rheb-GDP, inhibiting Rheb's stimulatory effects on mTORC1. TSC2 is 
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sensitive to growth factors and cellular energy but not to amino acids (4). In 
TSC2 knockout cells, amino acid deprivation still impairs mTORC1 signaling (61), 
suggesting that the primary site for amino acids is downstream from TSC2, 
possibly through Rheb (38).  
  Changes in cellular energy (AMP / ATP) are detected by the so called 
“cellular energy sensor” AMP activated Protein Kinase (AMPK). Three ways that 
AMP improves AMPK activity is by 1) making AMPK a better substrate for the 
upstream kinase, liver kinase B1 (LKB1); 2) allosteric activation of the 
phosphorylated enzyme; and 3) inhibition of dephosphorylation by protein 
phosphatases (22). Conversely, cellular ATP inhibits these processes (22). 
Phospho-AMPK acts to phosphorylate TSC1/2, resulting in inhibition of Rheb and 
mTORC1 signaling (69). AMPK is also known to stimulate eEF2K by 
phosphorylation of a Ser 398 residue, resulting in increased phosphorylation 
(inhibition) of eEF2 and translation elongation (9). Considering that protein 
turnover is a metabolically costly process, accounting for approximately one 
quarter of resting energy expenditure (68), it is logical that a cell would suppress 
protein synthesis activity during an energy deficit to preserve critical functions.  
  Hormones and growth factors are also important regulators of translation 
and mTORC1 signaling. A particularly important hormone is insulin, which 
activates Akt (also known as protein kinase B, PKB). Akt inhibits TSC1/2, 
allowing increased activation of Rheb and mTORC1 (25). During growth, 
anabolic hormones drive development of muscle and bone. However, as growth 
ends, the anabolic drive is lost and basal levels of hormones become largely 
ineffective in stimulating protein synthesis in structural tissues (32). Accordingly, 
in adult populations diet and physical activity become the limiting factors for 
maintaining muscle mass (32).  
  Consumption of dietary protein is known to stimulate translation and MPS. 
In particular, dietary Leu is known to be a critical determinant of MPS (3). 
Subsequent sections will analyze Leu metabolism, the mechanisms of Leu 
stimulated MPS, and dietary Leu experiments in clinical trials.   
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LEUCINE METABOLISM 
  Leu has numerous metabolic roles with particular importance in skeletal 
muscle. Like all amino acids, Leu is essential as a building block for synthesis of 
new proteins. Beyond this substrate role, Leu provides energy in the form of a 
keto-acid as a fuel for skeletal muscle (2, 58), modulates the insulin to mTORC1 
signal cascade (39, 64), and serves as a donor of an amino group for production 
of alanine or glutamine (2, 23) (Fig. 1.1). In each of these pathways, the impact 
of Leu is proportional to availability and dependent on intracellular concentration.  
  The multiple roles of Leu illustrate the unique metabolism of branched-
chain amino acid (BCAA) (8). Catabolism of most amino acids occurs in the liver 
facilitating disposal of the amino-nitrogen group in the urea cycle. However, the 
liver lacks the branched-chain aminotransferase (BCAT) enzyme required to 
initiate BCAA degradation. After a meal, amino acid degradation accelerates in 
the liver and enterocytes, blunting post-prandial swings in amino acid 
concentrations. Nearly 99% of glutamine, 75% of threonine and 50% of 
phenylalanine are lost to degradation or protein synthesis on the first pass 
through the visceral bed (18, 41). However, absence of the BCAT in liver results 
in over 70% of Leu and the other two BCAA, valine and isoleucine, reaching the 
systemic circulation. This is a striking metabolic difference for these amino acids 
which becomes even more remarkable with the realization that the three BCAA 
account for over 20% of total dietary protein.  
  Post-prandial changes in free Leu serve as an important nutrient signal to 
skeletal muscle. After a meal, plasma and intracellular BCAA concentrations rise 
in proportion to their meal content. The rise in intracellular Leu is the signal that 
triggers initiation of both muscle protein synthesis (MPS) and BCAA oxidation 
(60). Parallel activation of both the anabolic response for muscle protein 
synthesis and the degradation of the BCAA allows the post-prandial Leu 
concentration to initiate muscle protein synthesis, but assures that intracellular 
Leu levels return to baseline before the next meal (46).   
Increased BCAA oxidation is triggered by transamination of Leu to 
ketoisocaproate (KIC) mediated by BCAT. Increased KIC levels in skeletal 
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muscle have been shown to increase oxidation of all three BCAA (Leu isoleucine, 
and valine) by allosteric activation of branched-chain α-keto-acid dehydrogenase 
(BCKDH), which is responsible for the non-reversible oxidation of all three BCAA 
into their respective keto acids (1, 20). While all three keto-acids of Leu, 
isoleucine, and valine can increase BCKDH activity, research shows that KIC is a 
much stronger stimulus (1).  
 
LEUCINE AND MUSCLE PROTEIN SYNTHESIS 
  During stages of development, muscle and bone growth is driven by 
anabolic hormones including insulin, growth hormone, and steroid hormones (32, 
43). Later in life, basal levels of hormones become mostly ineffective at 
stimulating muscle growth; rather, diet and exercise become limiting factors for 
maintaining optimal protein turnover for repair, remodeling and recovery (32, 43). 
In particular, dietary Leu becomes an important regulator of muscle protein 
health in adults (33).   
  Leu is a potent stimulator of mTORC1 kinase activity, resulting in 
improved translation (17, 45). Numerous animal studies demonstrate the 
importance of a rapid rise in plasma Leu to initiate muscle protein synthesis (17, 
19). Crozier et al. (17) evaluated oral doses of free Leu ranging from 5% to 100% 
of the daily Leu requirement on regulation of translation initiation of muscle 
protein synthesis. They found that a single oral dose of Leu at 10% to 25% of the 
daily requirement produced maximum stimulation of muscle protein synthesis. 
They also found that the maximum stimulations of muscle protein synthesis 
related to maximum activation of the mTORC1 signal pathway at translation 
initiation factors p70S6K1 and eIF4E corresponding with 2- to 3-fold increases of 
plasma Leu above fasted values. Changes in plasma Leu act as a signal for 
activation of mTORC1 and represent an important criterion of protein quality for 
muscle health. Increases in plasma Leu above the threshold for mTORC1 
activation produce no additional effects on initiation factors or maximum rates of 
muscle protein synthesis.      
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EVIDENCE FOR THE LEUCINE THRESHOLD IN CLINICAL TRIALS  
  As demonstrated, Leu is a potent stimulator of MPS. Indeed, research has 
shown evidence for a dietary “threshold” of Leu required for stimulation of MPS. 
Evidence for defining the adult meal threshold for Leu derives from studies of 
catabolic conditions induced by acute exercise (63), extended bed rest (48), or 
aging (56). Oral ingestion or intravenous administration of 15 g of EAA produces 
a hyperaminoacidemia sufficient to stimulate muscle protein synthesis and 
produces a whole body anabolic state (6). These studies provided a complete 
mixture of EAA containing at least 2.5 g of Leu. Subsequent studies have 
established that the response threshold for muscle protein synthesis requires at 
least 15 g of EAA (or approximately 30 g of protein), while a much larger protein 
meal (90 g of protein) does not produce additional stimulation (62). Doses of EAA 
less than 7.5 g (or approximately 15 g of protein and less than 1.0 g of Leu) fail to 
stimulate muscle protein synthesis (27, 49).   
  While Leu stimulates muscle protein synthesis in acute studies, the 
efficacy of prolonged administration is less clear. Leu supplementation in clinical 
trials with chronic conditions such as liver disease, sepsis, or frail elderly has not 
produced consistent long-term benefits (40, 51). Although chronic down 
regulation of muscle protein synthesis capacity is a likely complication with these 
studies. Still, sustained anabolic effects of Leu on muscle protein synthesis 
should produce changes in lean tissue mass.   
  The most unequivocal evidence for the benefit of optimal dietary protein 
and Leu at individual meals is derived from studies of weight management (33, 
35, 36). Diets designed to provide at least 2.5 g of Leu per meal have been 
shown to be highly beneficial during weight loss because of their ability to modify 
body composition. During the catabolic condition of weight loss, higher protein 
diets attenuate loss of lean tissue and partition weight loss to body fat when 
compared with commonly recommended high carbohydrate low fat protein diets 
(35).  
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LEUCINE AND MUSCLE PROTEIN DEGRADATION 
  While the effects of Leu on protein synthesis are well defined, an equally 
pertinent factor for determining muscle health is regulation of muscle protein 
degradation (MPD). Muscle tissue mass represents the net balance between 
MPS and MPD. The continuous process of building and replacing muscle protein 
allows muscle to repair and adapt to environmental conditions. Net protein 
balance is positive during growth when MPS exceeds MPD, while net balance is 
negative during weight loss or aging, when MPD exceeds MPS (47). While there 
is evidence that MPD may be a major factor in protein turnover during aging (15), 
nearly all research on the effects of protein or amino acid supplementation on 
protein turnover has focused on MPS. Therefore, further research is needed to 
understand how nutrition impacts MPD.  
In part, the lack of MPD research is due to the lack of accurate methods 
for measuring MPD. Previous studies have used whole body amino acid flux and 
turnover measurements, which may not accurately reflect amino acid metabolism 
in muscle (55). An alternate approach has been to examine key signals believed 
to be involved in the regulation of MPD. Specifically, research has focused on 
regulation of the ATP-dependent ubiquitin-proteosome-proteolytic pathway (37). 
The ubiquitin-proteosome pathway was discovered in the late 1970s by 
Hershko, Ciechanover and colleagues (14, 24), who demonstrated its role in 
catalyzing the degradation of abnormal proteins. Now the ubiquitin-proteosome 
pathway is recognized to account for the majority of intracellular protein 
degradation (57). In particular, this system is responsible for degradation of 
short-lived regulatory proteins (24), and for the slow and progressive turnover of 
the long-lived proteins that comprise the majority of the cells enzymes and 
structure, respectively (44, 57). This system becomes more active during 
accelerated breakdown of myofibrilar proteins during diseased states (44).  
The process of ubiquitination involves covalent attachment of ubiquitin – a 
small, compact, highly conserved polypeptide – to proteins, effectively “tagging” 
them for selective destruction in proteolytic complexes called proteasomes (12, 
37). To elaborate, this process requires a concerted action of 3 enzymes known 
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as ubiquitin conjugating enzymes E1, E2, and E3. First, ubiquitin proteins are 
activated by ATP dependent formation of a thiol ester with the ubiquitin-activating 
enzyme E1, an abundant 110 kD protein. E1 then transfers the activated 
ubiquitin molecule to an ubiquitin E2 carrier protein, which are smaller 14-20 kD 
proteins with high specificities. Finally, ubiquitin is transferred from E2 to a ε-
amino group of a lysine residue on the protein to be targeted for degradation.  A 
family of E3 ubiquitin-conjugating enzymes mediates transfer of ubiquitin from E2 
to the target protein. Subsequently, additional ubiquitin molecules are attached to 
the preceding ubiquitin molecule by E3, forming an ubiquitin polypeptide chain. 
Once 4 or more ubiquitin proteins have been attached to the target protein, the 
target protein is recognized for degradation by the proteolytic complexes called 
proteasomes. The 26S proteasome is considered the major proteolytic enzyme 
complex involved in intracellular protein degradation (37). 
Since discovery of the ubiquitin-protesome pathway, many studies have 
focused on its function and regulation – particularly, in states of muscle wasting. 
In this context, there is evidence suggesting that Leu has anti-proteolytic effects, 
including attenuation of the ubiquitin-protesome pathway (72). For instance, 
Combaret et al. (16) demonstrated that Leu supplementation in elderly rats 
completely prevented the rise in ubiquitin-proteosome expression associated with 
age. Further, Baptista et al. (5) showed that Leu supplementation in rats with 
immobilized hind limbs, attenuated muscle loss, protein ubiquitination, and 
expression of ubiquitin proteins.  
 
POSTPRANDIAL DURATION OF MUSCLE PROTEIN SYNTHESIS 
  Protein synthesis is an oscillating process, increasing after consumption of 
food, and decreasing in post-absorptive and fasting conditions. While complete 
meals providing ample protein and energy increase protein synthesis, it is 
unknown how long this response lasts, and what causes termination of the 
anabolic response. Bohé et al. (7) investigated this by intravenously infusing 
amino acids into adult humans for six hours. Plasma amino acid concentrations 
were raised 1.7 fold and then maintained throughout the allotted period of time. 
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MPS remained elevated 2.8 fold for 1.5 hours, but returned to basal levels for the 
remaining four hours. This suggests that mechanisms other than dietary amino 
acids determine the duration of protein synthesis. However, mechanisms 
underlying the discordance between elevated plasma amino acids and declined 
MPS are unknown.  
 
SUMMARY 
  This dissertation seeks to further elucidate the role of dietary Leu in 
regulation of skeletal muscle protein balance. Current knowledge underscores 
that Leu is a critical regulator of MPS. The mechanism appears to be through 
stimulation of mTORC1 signaling and translation initiation. There is also evidence 
that Leu can attenuate MPD and ubiquitin-proteosome signaling. However, most 
of this research has been done with purified Leu formulas or in vitro, and is 
untested with whole foods using in vivo feeding protocols. This dissertation seeks 
to explore the role of dietary Leu in regulation of skeletal muscle protein balance 
using whole food feeding models.  
  There is ample research on the early signaling effects of Leu on MPS; 
however, research has shown discordance between elevated plasma Leu and 
MPS at the end of the absorptive period. The mechanisms underlying these 
results are also unknown and this dissertation will explore mechanisms 
regulating the duration of translational control of protein synthesis using a unique 
feeding model in adult rats.  
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FIGURES 
 
Fig. 1.1. Leucine and insulin regulation of muscle protein synthesis. IRS-1 (insulin receptor 1); 
PI3-K (Phosphoinositide 3-kinase); Akt (protein kinase B, or PKB); tuberous sclerosis complex 1 
and 2 (TSC1/2); mTORC1 (mammalian target of rapamycin); eukaryotic initiation factor 4E 
binding protein 1 (4E-BP1); eukaryotic initiation factor 4E (eIF4E); Phosphorylated 70 kilodalton 
ribosomal protein S6 kinase (p70S6K1); ribosomal protein S6 (rpS6).  
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CHAPTER II:  
LEUCINE CONTENT OF DIETARY PROTEINS DETERMINES 
POSTPRANDIAL SKELETAL MUSCLE PROTEIN SYNTHESIS IN ADULT 
RATS 
 
INTRODUCTION 
Food proteins differ in many characteristics including amino acid content. 
Current measures of protein and amino acid requirements are based on 
minimum daily intake to maintain nitrogen balance and to prevent increases in 
plasma amino acids stimulating amino acid oxidation. These measurements 
focus on lysine, methionine, and threonine as the most limiting of the 
indispensable amino acids. The branched-chain amino acid (BCAA) leucine 
(Leu) is comparatively abundant in most proteins and unlikely to be limiting 
based on nitrogen balance or amino acid oxidation measurements.  
Although Leu is unlikely to be limiting new metabolic roles are being 
defined for Leu intakes above minimum requirements.  Among these roles, 
previous research suggests that a dietary threshold for Leu stimulation of muscle 
protein synthesis (MPS) may exist (14). Indeed, Leu is unique among amino 
acids as a modulator of the mTORC1 (mammalian target of rapamycin) signal 
cascade and MPS (8). Numerous in vivo studies demonstrate that oral or 
intravenous administration of free Leu stimulates mTORC1 activation of 
translation initiation factor eIF4E-BP1 (4E-BP1) and the 70 kilodalton ribosomal 
protein S6 kinase (S6K1). Titration studies of Leu regulation of MPS indicate that 
Leu stimulation of mTORC1 is dependent on increasing intracellular Leu 
concentrations and that stimulation requires approximately a doubling of plasma 
Leu above baseline (i.e. food deprived) values (5, 14). 
While the threshold response of mTORC1 and MPS to plasma Leu 
concentrations is established from studies using free Leu, the significance of this 
threshold activation in physiological meals with complex macronutrient and fiber 
mixtures is unknown. Accordingly, the present experiments utilized a meal-
feeding protocol with adult rats to examine the importance of the Leu content of a 
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meal on post-prandial plasma Leu concentrations, S6K1 and 4E-BP1 activation, 
and MPS stimulation. The test meals were designed to represent small breakfast 
meals (20% of daily energy) with a mixture of macronutrients (16% of energy 
from protein, 54% carbohydrates, 30% fats) consumed after a 12-h period of food 
deprivation. Experiment 1 used four proteins (wheat gluten, soy isolate, egg 
white, and whey protein isolate) selected to provide a range of Leu 
concentrations from 6.8% to 10.9% (w/w). We hypothesized that the Leu content 
of these meals with limited protein quantity and energy would predict MPS 
outcomes. While experiment 2 examined if supplementing the wheat protein 
meal (6.8% leu) with Leu to be equivalent to the whey protein meal (10.9% leu) 
would equalize peak plasma Leu concentration, signaling responses, and MPS.  
 
MATERIALS AND METHODS 
Animals. Male rats (250 ± 12 g, 9-11 weeks of age) were purchased from 
Harlan-Teklad (Indianapolis, IN) and maintained at 24°C with a 12-h light:dark 
cycle and free access to water.  The animal facilities and protocol were reviewed 
and approved by the Institutional Animal Care and Use Committee of the 
University of Illinois at Urbana-Champaign.  
Meal training protocol. Rats were trained to consume 3 meals/d consisting 
of a 4 g meal consumed between 07:00 and 07:20 h followed by free access to 
food from 13:00 to 14:00 and 18:00 to 19:00 (10). Rats consumed ~17 g/d of total 
diet equivalent to ad libitum intake.  All diet treatments provided 16/54/30% of 
energy from protein, carbohydrates and fats, respectively.  
Experimental Treatments. Experiment 1 examined post-prandial changes 
in MPS, plasma leu, and translation factors in rats fed meals differing in source of 
protein: wheat (n=10), soy (n=10), egg (n=11), or whey protein (n=11) (Table 
2.1). Wheat gluten diets were supplemented with lysine to meet National 
Research Council (NRC) requirements and all diets exceeded minimum 
indispensable amino acid requirements (Supplemental Table 2.5) and to equal 
the lysine content of the whey protein isolate (Table 2.2). A baseline food-
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deprived control group was also adapted to meal-feeding using whey protein 
(n=10).  Rats were fed the respective diets for 14 d. On the experiment day, rats 
were food-deprived for 12 h and then fed their normal 4 g breakfast meal. The 
food-deprived controls received no breakfast meal. The treatment groups 
received 0, 46, 54, 60, and 74 mg of Leu for the food-deprived controls, wheat, 
soy, egg, and whey groups, respectively. Rats were killed 90 min after 
consumption of the meal and blood and tissue samples collected. Tissues were 
then stored at -80°C for later analyses. MPS was measured at 0 and 90-min 
time-points as described below.  
Experiment 2 examined supplementing the wheat gluten meal with Leu to 
determine if matching Leu content of the wheat meal would yield similar anabolic 
responses as whey. In addition, time-course of changes in plasma Leu, MPS, 
and translation initiation factors were examined to evaluate digestion and 
absorption patterns for the wheat, whey and wheat + Leu meals. All rats were 
adapted to meal feeding using wheat gluten as the protein source. Wheat gluten 
was supplemented with lysine as in Experiment 1.  
After 6 d of adaptation to meal feeding, rats were assigned to treatment 
groups based on body weight. Animals (n = 5-6 per group) were food deprived 
for 12 h and then groups randomly assigned to either food deprived controls or 
fed one of three 4 g meals with 16% protein coming from wheat gluten, wheat 
gluten supplemented with Leu (WGL) (Ajinomoto, Chicago, IL) (total = 10.9% 
Leu), or whey protein (Table 2.1). The whey protein and wheat gluten (WGG) 
conditions were both supplemented with glycine (Sigma-Aldrich, St. Lois, MO) to 
make test meals isonitrogenous and isoenergetic with the WGL condition. At 30, 
90, and 135 min after consumption of the meal, rats were euthanized and blood 
and tissues harvested. Gastrocnemius muscles were dissected and snap frozen 
in liquid nitrogen. Tissues were then stored at -80°C until analyzed. MPS was 
measured at 0 and 90-min time-points.  
Administration of metabolic tracer and sample collection. Protein synthesis 
was measured in gastrocnemius muscles using the flooding dose method (9). A 
100% enriched L-[2H5]-phenylalanine solution (150 mmol/L; Cambridge Isotopes, 
  21 
Andover, MA) was administrated at 150 µmol/100 g body weight and injected via 
tail vein (1 mL/100 g body weight). After 10 min rats were killed by decapitation 
and hind limbs quickly removed and immersed in an ice-water mixture. Muscles 
were removed from cooled hind limbs, frozen in liquid N2, and stored at -80°C.   
 Determination of MPS. Frozen muscle was powdered in liquid nitrogen 
and protein precipitated with cold (4°C) perchloric acid (30 g/L, 1 mL per 50 mg 
muscle tissue). The resulting supernatant and protein pellet were prepared for 
gas chromatography mass spectroscopy (GC-MS) analyzes as described 
previously (6, 12). Enrichment of L-[2H5]-phenylalanine in the muscle hydrolysate 
was measured by GC-MS using a 6890N GC and a 5973N mass detector 
(Agilent Technologies Santa Clara, CA). Samples were run under electron impact 
ionization in splitless mode and phenylethylamine ions with mass-to-charge ratio 
(m/z) 106 (m + 2) and 109 (m + 5) were monitored for enrichment.  
Muscle supernatants were used for determination of intracellular free 
phenylalanine enrichment. Free amino acids were purified by ion exchange resin 
solid phase extraction (SPE) using EZ:faastTM amino acid analysis sample 
testing kit (Phenomenex Inc. Torrance, CA, USA) and 2H5-phenylalanine 
enrichment was determined using a propyl chloroformate derivative with GC-MS 
monitoring of ions at m/z 206 (m) and 211 (m+5) (13).  
Rates of muscle protein synthesis (MPS) were determined from the rate of 
incorporation of L-[2H5]-phenylalanine into total mixed muscle protein as 
described previously (4). The time from injection of the metabolic tracer until 
tissue cooling was recorded as the actual time for L-[2H5]-phenylalanine 
incorporation.  MPS, defined as the percentage of tissue protein renewed each 
day, were calculated according to the formula: MPS=(Eb x 100)/(Ea x t) where t is 
the time interval between isotope injection and snap freezing of muscle 
expressed in days and Eb and Ea are the enrichments of [2H5]-phenylalanine in 
hydrolyzed tissue protein and in muscle free amino acids, respectively. 
Plasma measurements. Plasma was obtained from trunk blood by 
centrifugation at 1800 x g for 10 min at 4°C. Plasma insulin concentrations were 
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analyzed using a commercial RIA kit for rat insulin (Linco Research, St. Charles, 
MO). Plasma glucose (Thermo Fisher Scientific, Middletown, VA) was 
determined by the glucose oxidase method. Plasma amino acid concentrations 
were analyzed by HPLC using a Waters 2475 Fluorescence detector (17). 
Western blot analysis. Muscle supernatants were subjected to protein 
immunoblot analyses as described previously (1, 3) using rabbit polyclonal 
antibodies for 4E-BP1 (1:1,000 dilution) (Bethyl Labs, Montgomery, TX), S6K1 
(1:1,000 dilution) (Bethyl Labs, Montgomery, TX), and Akt (1:1,000 dilution) (Cell 
Signaling, Boston, MA). Anti-rabbit IgG, HRP-linked secondary antibody was 
purchased from Cell Signaling (1:2,000 dilution) (Boston, MA). 
Statistical analysis.  All data were analyzed by SPSS 15.0 (Chicago, IL) 
software package for Windows. For Experiment 1, a one-way ANOVA was 
performed with the treatment groups as the independent variables. For 
Experiment 2, a one-way ANOVA was performed for MPS, with treatment groups 
as the independent variables. Other comparisons for Experiment 2 utilized a 3 x 
4 (ie. experimental groups: WGG, WGL, and whey x time: 0, 30, 90, and 135 
min) repeated measures ANOVA to determine within and between group 
differences. When a significant overall effect was detected, differences among 
individual means were assessed using Fisher’s LSD post hoc test. Data sets 
were tested for normal distribution and variance homogeneity using Levene’s 
test. When variances were not homogeneous, means were compared using a 
Games-Howell test. Significance was set at P<0.05 for all statistical tests. All 
values are presented as means ± SEM.   
RESULTS  
Experiment 1 compared isonitrogenous, isoenergetic meals containing 
wheat gluten, soy protein isolate, egg white protein, or whey protein isolate as 
the protein source on the potential to stimulate translation initiation and protein 
synthesis in skeletal muscle. After consumption of a 4 g meal providing 20% of 
daily energy and containing 16% of energy as protein, plasma Leu increased in 
rats fed egg or whey proteins but not in wheat or soy groups. Similar post-
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prandial patterns occurred for each of the BCAA with whey producing the highest 
concentrations at 90 min after the meal (i.e. whey > egg > soy > wheat) (Table 
2.3).   
 Other plasma amino acids varied among the groups largely in proportion 
to the amino acid content of the protein source (Table 2.3). Lysine was different 
between rats fed soy and whey; with rats fed whey having the greatest 
concentration of post-prandial lysine and rats fed soy having the lowest lysine 
levels. The wheat group reflects the diet supplementation. Plasma methionine 
concentrations were only increased in rats fed egg with the other groups not 
being different from food deprived controls (Table 2.3). Plasma threonine was 
increased by feeding egg or whey with highest concentrations observed in rats 
fed whey protein. 
 MPS increased in rats fed egg or whey with the highest value observed for 
the whey group (Fig. 2.1). The MPS response was consistent with 
phosphorylation of the mTORC1 signaling targets 4E-BP1 (Fig. 2.2A) and S6K1 
(Fig. 2.2B). Phosphorylation of S6K1 increased after egg or whey meals but not 
wheat or soy with peak values obtained in the whey protein group. 4E-BP1 
phosphorylation increased in all groups with whey greater than wheat or soy and 
egg greater than soy but not different from wheat or whey.   
 Plasma insulin concentrations were above baseline at 90 min after the 
meal in all groups except soy, which was not different from food-deprived 
controls (Table 2.3). Insulin was not significantly different between rats fed 
wheat, soy, egg, or whey.  Similarly, plasma glucose was increased above 
baseline concentrations in all groups except for rats fed soy, which was not 
different from baseline, wheat, egg, or whey groups (Table 2.3). 
Akt activation (i.e. phosphorylation at Ser473) was increased in rats fed 
soy compared with rats fed egg, whey, or the food-deprived controls (Fig. 2.3). 
Rats fed wheat had intermediate levels of Akt phosphorylation that was not 
different from baseline or soy groups but greater than egg or whey groups.  
Experiment 2 compared meals containing wheat (WGG), wheat + Leu 
(WGL), or whey (10.9% Leu) on the potential to increase plasma Leu, signaling 
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responses, and MPS over a 135-min time-course. At all time-points, WGL and 
whey groups had greater increases in plasma Leu than WGG or food-deprived 
controls; but WGL and whey did not differ from each other (Table 2.4). Likewise, 
MPS increased in whey and WGL groups but not in WGG (Fig. 2.4).  
Plasma amino acids were consistent with Experiment 1 except Ile and Val 
concentrations tended to be lower in the WGL group compared with WGG. Post-
prandial insulin concentrations at 30 min were greater in whey protein and WGL 
fed rats, than WGG rats (Table 2.4). Likewise, Akt signaling tended to be greater 
30-min post-meal in whey protein and WGL fed rats than WGG fed rats, but this 
did not reach statistical significance (p>0.05) (Fig. 2.5). 
 
DISCUSSION 
 Leu is established as a signaling factor for translation initiation and MPS in 
skeletal muscle (1, 5, 11). However, the majority of this research has been done 
with large supplemental doses of free Leu, and the significance of this threshold 
activation in physiological meals with complex macronutrient and fiber mixtures is 
unknown. Accordingly, the present studies examined responses of plasma amino 
acids, translation initiation factors, and MPS in adult rats fed complete meals with 
protein sources selected for differences in Leu content. The primary finding of 
this research is that meals with different protein sources stimulate anabolic 
signaling and MPS in proportion to the Leu content of the meal and post-prandial 
changes in plasma Leu concentrations.  
 Experiment 1 examined the MPS and anabolic signaling responses to 
isonitrogenous meals containing wheat, soy, egg, or whey proteins, which were 
selected to provide a range of Leu concentrations from 6.8% to 10.9% (w/w). The 
Leu content of the protein sources predicted plasma Leu concentrations and 
anabolic responses in skeletal muscle. Consistent with plasma Leu and MPS, 
post-prandial S6K1 phosphorylation increased in egg or whey treatment groups 
by 22% and 58%, respectively, whereas rats receiving wheat or soy had no 
increase in S6K1 phosphorylation. Phosphorylation of 4E-BP1 increased after 
the meal in all groups with maximum phosphorylation of 4E-BP1 in the whey 
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group. The present study demonstrates that after a small meal with limited 
protein content, MPS responds to post-prandial changes in plasma Leu 
concentrations that reflect the Leu content of the individual proteins. These 
findings support a concept for a minimum meal threshold for Leu to stimulate 
post-prandial MPS.   
 Further support for the importance of Leu content of protein for MPS is 
available from both animal (3, 14) and human (15, 18) studies. Norton et al. (14) 
conducted a dose response study examining wheat and whey proteins fed at 
10%, 20% and 30% of dietary energy. At isonitrogenous intakes, whey protein 
produced higher levels of plasma Leu, mTORC1 signaling, and MPS than wheat. 
However, MPS was not different comparing meals with 30% wheat vs 20% whey 
consistent with the Leu difference between wheat (6.8% Leu) and whey (10.9% 
Leu). Similar support for Leu as a signal to initiate an anabolic meal response 
has been observed for young men consuming whey, soy and casein after 
exercise (18) and in older men consuming whey or casein hydrolysates (15).  
In the present study with dietary protein limited to 16% of energy, the egg 
protein meal (8.8% Leu) increased plasma Leu to 146 µmol/L stimulating MPS, 
while soy protein (~8.0% Leu) did not increase plasma Leu or MPS. Anthony et 
al. (3) compared mTORC1 signaling and MPS in rats fed 20% soy vs whey after 
exercise. Interestingly, with dietary protein at 20% of energy, post-prandial 
plasma Leu in the soy group was 150 µmol/L representing approximately a 
doubling of Leu concentration above baseline and there was no difference in 
MPS between soy and whey. Further supporting a “threshold” of Leu intake 
required to increase plasma Leu and stimulate MPS.  
 While dietary Leu appears to be a critical factor to account for the post-
meal MPS response, there is evidence that orally administered isoleucine (Ile) 
also activates mTORC1 signaling, although not as powerfully as Leu (1). In 
complete proteins, Ile is typically present in proportion to the Leu content, 
allowing the possibility that Ile may in part contribute to the mTORC1 signaling 
and MPS. However, in the current study, rats fed soy significantly increased post-
prandial plasma Ile concentration with no corresponding increase in mTORC1 
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signaling or MPS. This is consistent with previous research that only Leu among 
the EAA was able to increase MPS when infused in rats (8). In the present study 
with complete meals, only the post-prandial changes in plasma Leu predicted 
changes in mTORC1 signaling and stimulation of MPS.  
 Beyond Leu content, food proteins differ in many characteristics including 
distribution of other indispensable amino acids, differences in gastric emptying or 
digestibility, and insulinogenic properties. Experiment 2 was designed to isolate 
the importance of Leu within a meal and to test the significance of gastric 
clearance and digestibility. Experiment 2 demonstrated that supplementing the 
wheat protein meal with Leu to equalize the Leu density of the meals (WGL vs 
whey) equalized the 90-min post-prandial MPS response (Fig. 4).  
 If gastric emptying and digestibility differed between wheat and whey 
protein, then the timing of peak plasma Leu concentrations should be different for 
the WGG and WGL vs Whey groups presumably with the WGG and WGL groups 
exhibiting delayed plasma amino acid appearances compared with the Whey 
treatment. However, for each of the treatment groups, peak plasma Leu 
concentration occurred 30 min after the meal, and there was a strong correlation 
with Leu content of the meal and peak plasma Leu concentration (r = 0.919; P < 
0.05). Indeed, at all time-points, WGL and whey protein groups had greater rises 
in plasma Leu than WGG and fasted values and were not different from each 
other. Furthermore, the 30-min peak plasma Leu response for the WGL group 
achieved ~ 91% of the predicted value, based on the plasma leu response of the 
whey meal (which had equal dietary Leu to WGL). These finding are consistent 
with published digestibility values for wheat gluten (98%), whey protein isolate 
(97%), egg white protein (100%), and soy protein isolate (96%) (7) indicating that 
digestibility is not significantly different among these isolated proteins.  
Insulin signaling was greatest 30-min post-meal in the whey and WGL 
groups relative to baseline and WGG groups. Akt signaling also tended to be 
greater 30 min post-meal in whey and WGL groups compared with the WGG 
group, but did not reach statistical significance (p>0.05). Prior research suggests 
that post-prandial increases in insulin play a permissive role in Leu-dependent 
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stimulation of protein synthesis and translation initiation (2). Therefore, the 
heightened insulin response in whey protein and WGL fed rats may contribute to 
greater rates of mTORC1 signaling and MPS.  
In summary, Experiment 1 demonstrates that within a small meal, with 
protein quantity set at 16% of energy and limited by meal size, the Leu content of 
individual proteins determines translation initiation signaling in skeletal muscle 
and ultimately post-prandial MPS. To our knowledge this is the first study to show 
the significance of Leu as a factor of protein quality within meals containing 
complete macronutrient and fiber mixtures. While experiment 2 demonstrates 
that Leu supplementation of a meal containing a Leu-poor protein enhances 
translation initiation and MPS. These findings support the hypothesis that the Leu 
density of dietary proteins is important to adult protein utilization and highlights 
the need for long-term studies examining the impact of Leu density on muscle 
health and body composition.  
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FIGURES AND TABLES 
 
 
Fig. 2.1. Rates of muscle protein synthesis in gastrocnemius muscle of rats fed a complete meal 
containing wheat, soy, egg, or whey proteins. Data are means ± SEM; n = 9-10. Labeled means 
without a common letter differ, P<0.05.   
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Fig. 2.2.  Phosphorylation states of 4E-BP1 (A) and p70S6K1 (B) in gastrocnemius muscle of rats 
fed a complete meal containing wheat, soy, egg, or whey proteins. Data are means ± SEM; n = 9-
10. Labeled means without a common letter differ, P<0.05.   
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Fig. 2.3.  Phosphorylation states of Akt in gastrocnemius muscle of rats fed a complete meal 
containing wheat, soy, egg, or whey proteins.  Data are means ± SEM; n = 9-10.  Labeled means 
without a common letter differ, P<0.05.   
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Fig. 2.4.  Rates of muscle protein synthesis in gastrocnemius muscle of rats fed isonitrogenous 
meals containing wheat gluten supplemented with glycine (WGG), wheat supplemented with 
leucine (WGL), or whey protein supplemented with glycine. Data are means ± SEM; n = 5-6.  
Labeled means without a common letter differ, P<0.05.   
  
  34 
 
Fig. 2.5.  Phosphorylation states of Akt in gastrocnemius muscle of rates fed isonitrogenous 
meals containing wheat gluten supplemented with glycine (WGG), wheat supplemented with 
leucine (WGL), or whey protein supplemented with glycine. Data are means ± SEM; n = 5-6. 
Labeled means without a common letter differ within time-points, P<0.05. * Indicates different 
from fasted (P<0.05).  
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Table 2.1. Composition of animal diets 
 
Component Wheat Diet Soy Diet Egg Diet Whey Diet 
  g/kg   
Vital Wheat Gluten1 190.2 0.0 0.0 0.0 
Soy Protein Isolate2 0.0 185.3 0.0 0.0 
Egg White Solids3 0.0 0.0 195.6 0.0 
Whey Protein Isolate4 0.0 0.0 0.0 188.8 
L-Lysine5 10.1 0.0 0.0 0.0 
Cornstarch 316.7 331.7 321.4 328.2 
Maltodextrin 134.1 134.1 134.1 134.1 
Sucrose 101.5 101.5 101.5 101.5 
Soybean Oil 140.9 140.9 140.9 140.9 
Cellulose (Fiber) 53.7 53.7 53.7 53.7 
Mineral Mix6 37.6 37.6 37.6 37.6 
Vitamin Mix6 10.7 10.7 10.7 10.7 
Choline Bitautrate 2.7 2.7 2.7 2.7 
Biotin7  0.0 0.0 0.016 0.0 
 
1Vital Wheat Gluten purchased from Honeyville Grain, Honeyville, UT.  83.4% protein, 7.6% 
carbohydrate, 9% other. 
2Soy Protein Isolate provided by Archer Daniels Midland Company, Decatur, IL.  91.6% protein, 
1.4% carbohydrate, 7% other.  
3Egg White Solids purchased from Harlan-Teklad, Madison, WI.  87.8% Protein, 4.5% 
carbohydrate, 7.7% other. 
4Whey Protein Isolate provided by Perham, Perham, MN.  89.9% protein, 3.8% carbohydrate, 
6.3% other. 
5Vital Wheat Gluten supplemented with 6.3g L-lysine/100g protein to match Whey Protein Isolate.   
6Mineral and Vitamin supplements (16) from Harlen-Teklad, Madison, WI. 
7Egg White Solids supplemented with 16.0 mg biotin/kg diet.  
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Table 2.2. Amino acid compositions of protein sources 
 
Amino Acid Vital Wheat Gluten1 
Soy Protein 
Isolate2 
Egg White 
Solids3 
Whey Protein 
Isolate4 
  g/100g Protein   
Alanine 3.1 4.0 6.1 4.9 
Arginine 4.7 7.5 5.8 2.4 
Aspartate 4.0 11.5 10.3 10.6 
Cysteine 1.9 1.3 4.4 2.5 
Glutamate + Glutamine 31.7 19.2 13.1 16.9 
Glycine 3.8 4.1 3.5 1.8 
Histidine 1.8 2.5 2.3 2.0 
Isoleucine 3.0 4.8 5.3 6.2 
Leucine 6.8 8.0 8.8 10.9 
Lysine5 2.8 (+6.3) 6.3 6.5 9.1 
Methionine 1.9 1.3 3.8 2.0 
Phenylalanine 4.4 5.2 5.9 3.3 
Proline 9.4 5.2 3.8 5.6 
Serine 3.9 5.4 6.9 4.7 
Threonine 2.6 3.8 4.5 6.4 
Tryptophan 1.3 1.2 1.6 1.7 
Tyrosine 2.4 4.8 4.0 3.0 
Valine 4.5 4.7 6.8 6.0 
 
1Vital Wheat Gluten purchased from Honeyville Grain, Honeyville, UT.  83.4% protein, 7.6% 
carbohydrate, 9% other. 
2Soy Protein Isolate provided by Archer Daniels Midland Company, Decatur, IL.  91.6% protein, 
1.4% carbohydrate, 7% other.  
3Egg White Solids purchased from Harlan-Teklad, Madison, WI.  87.8% Protein, 4.5% 
carbohydrate, 7.7% other. 
4Whey Protein provided by Perham, Perham, MN.  89.9% protein, 3.8% carbohydrate, 6.3% 
other. 
5Vital Wheat Gluten supplemented with 6.3g L-lysine/100g protein to match Whey Protein Isolate.   
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Table 2.3. Selected plasma essential amino acid1, insulin2, and glucose3 concentrations 90 min 
after feeding complete meals containing wheat, soy, egg, or whey protein4 
 Baseline5 Wheat Soy Egg Whey 
Leucine 84 ± 4.6c 78 ± 4.3c 84 ± 5.6c 146 ± 8.4b 192 ± 11.4a 
Isoleucine 56 ± 3.4d 50 ± 2.9d 74 ± 4.0c 121 ± 6.3b 144 ± 8.2a 
Valine 117 ± 8.2cd 95 ± 5.2d 143 ± 8.1c 295 ± 14.2b 248 ± 13.7a 
∑ BCAA 257 ± 16.0bc 223 ± 12.1c 301 ± 17.4b 562 ± 28.5a 584 ± 33.0a 
      
Lysine 510 ± 29.8ab 527 ± 23.8ab 419 ± 37.2b 495 ± 35.6ab 549 ± 29.3a 
Methionine 51 ± 2.9bc 46 ± 2.8bc 38 ± 4.1c 86 ± 6.8a 52 ± 5.2b 
Threonine 252 ± 13.7c 269 ± 30.4bc 349 ± 40.6bc 357 ± 28.3ab 538 ± 51.2a 
      
Insulin   140 ± 10.5b 178 ± 9.0a 161 ± 11.0ab 184 ± 12.0a 170 ± 7.2a 
Glucose   7.8 ± 0.58b 9.9 ± 0.50a 8.5 ± 0.67ab 9.7 ± 0.77a 9.4 ± 0.40a 
 
1Plasma amino acids expressed as µmol/L 
2Plasma insulin expressed as pmol/L 
3Plasma glucose expressed as mmol/L 
4Values expressed as means ± SEM, n=8-10.  Labeled means without a common letter differ 
(P<0.05). 
512 h food-deprived controls.  
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Table 2.4. Post-prandial changes for plasma amino acids1 and plasma insulin2,3 
__________________________________________________________________________________________________ 
              Fasted4       Whey    Wheat                        Wheat+Leu 
Time (min)        30       90           135      30   90          135     30  90         135 
__________________________________________________________________________________________________ 
Leu 86±4   226±17a*  164±26a* 173±22a*  151±8b*     86±6b     99±5b 211±8a*  137±8a*  148±3a* 
Ile        69±2   166±11a*  104±4a*   134±16a*  110±6b*     66±3b        86±6b      98± 6b*   60±4b*    67±1c 
Val         117±5   234±17a*  161±5a*   186±19a*   154±8b*     91±3b     104±7b     131±18b   77±6b*   77±2c* 
Lys        608±24 1083±78*   593±34    688±62    930±64*   553±28   698±14  933±67   597±55  726±48 
Met 49±2   102±6a*      62±2a*         80±5a*            72±3b*    42±1b         52±3b               71±3b*     44±4b     46±2b 
Thr         309±9   594±73*   567±18a*   554±38a     383±21    330±18b   314±22b   387±12    382±20ab 308±13b 
Insulin      35±2     50±8a*      41±6b       40±9            42±7b     40±6b       45±6           56±19a*  50±14a*   47±14 
___________________________________________________________________________________________________ 
 
1Plasma amino acids expressed as µmol/L 
2Plasma insulin expressed as pmol/L 
3Data are means ± SEM; N=5-6.  
412 hour food-deprived controls.  
Means without a common letter differ between treatments within time-points, (P<0.05).  
* Indicates different from fasted (P<0.05) 
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Supplemental Table 2.5. Comparison of test diet amino acid compositions with NRC 
requirements1,2 
 
Amino Acid  Wheat 
Diet 
Soy  
Diet 
Egg  
Diet 
Whey  
Diet 
NRC 
Requirement 
   g/kg diet    
Phenyalanine + Tyrosine  11.5 17.0 16.8 10.7 1.9 
Histidine  3.1 4.2 3.9 3.4 0.8 
Isoleucine  5.1 8.1 9.0 10.5 3.1 
Leucine  11.5 13.6 14.9 18.5 1.8 
Lysine3  4.7(+10.6) 10.7 11.0 15.4 1.1 
Methionine + Cysteine  6.5 4.4 13.9 7.6 2.3 
Threonine  4.4 6.5 7.6 10.9 1.8 
Tryptophan  2.2 2.0 2.7 2.7 0.5 
Valine  7.6 8.0 11.5 10.2 2.3 
 
1Table 2-2 from Nutrient Requirements of Laboratory Animals Fourth Revised Edition (1). 
2Values calculated for 300 g rat at maintenance. 
3Vital Wheat Gluten supplemented with 10.6 g L-lysine/kg diet to match Whey Protein Isolate.   
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CHAPTER III:  
IMPACT OF DIETARY LEUCINE ON THE UBIQUITIN-PROTEOSOME 
PATHWAY FOR PROTEIN DEGRADATION IN SKELETAL MUSCLE 
 
INTRODUCTION 
   Chapter II demonstrated that consuming proteins with greater leucine 
(Leu) densities resulted in improved anabolic signaling and rates of muscle 
protein synthesis (MPS). However, while the effects of Leu on MPS are 
important, an equally pertinent factor for determining muscle health is regulation 
of muscle protein degradation (MPD). Muscle tissue mass represents the net 
balance between MPS and MPD. The continuous process of building and 
replacing muscle protein allows muscle to repair and adapt to environmental 
conditions. Net protein balance is positive during growth when MPS exceeds 
MPD, while net balance is negative during weight loss or aging, when MPD 
exceeds MPS (24). While there is evidence that MPD may be a major factor in 
protein turnover during aging (6), nearly all research on the effects of protein or 
amino acid supplementation on protein turnover has focused on MPS. Therefore, 
further research is needed to understand how nutrition impacts MPD.  
In part, the lack of MPD research is due to the inability to accurately 
measure MPD. Previous studies have used whole body amino acid flux and 
turnover measurements, which may not accurately reflect amino acid metabolism 
in muscle (27). An alternate approach has been to examine key signals believed 
to be involved in the regulation of MPD. Specifically, research has focused on 
regulation of the ATP-dependent ubiquitin-proteosome-proteolytic pathway (18). 
The ubiquitin-proteosome pathway was discovered in the late 1970s by 
Hershko, Ciechanover and colleagues (4, 16), who demonstrated its role in 
catalyzing the degradation of abnormal proteins. Now the ubiquitin-proteosome 
pathway is recognized to account for the majority of intracellular protein 
degradation (28). In particular, this system is responsible for degradation of 
short-lived regulatory proteins (16), and for the slow and progressive turnover of 
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the long-lived proteins that comprise the majority of the cells enzymes and 
structures, respectively (20, 28). This system becomes more active during 
accelerated breakdown of myofibrilar proteins during diseased states (20).  
The process of ubiquitination involves covalent attachment of ubiquitin – a 
small, compact, highly conserved polypeptide – to proteins, effectively “tagging” 
them for selective destruction in proteolytic complexes called proteasomes (3, 
18). To elaborate, this process requires a concerted action of 3 enzymes known 
as ubiquitin conjugating enzymes E1, E2, and E3. First, ubiquitin proteins are 
activated by ATP dependent formation of a thiol ester with the ubiquitin-activating 
enzyme E1, an abundant 110 kD protein. E1 then transfers the activated 
ubiquitin molecule to an ubiquitin E2 carrier protein, which are smaller 14-20 kD 
proteins with high specificities. Finally, ubiquitin is transferred from E2 to a ε-
amino group of a lysine residue on the protein to be targeted for degradation.  A 
family of E3 ubiquitin-conjugating enzymes mediates transfer of ubiquitin from E2 
to the target protein. Subsequently, additional ubiquitin molecules are attached to 
the preceding ubiquitin molecule by E3, forming an ubiquitin polypeptide chain. 
Once 4 or more ubiquitin proteins have been attached to the target protein, the 
target protein is recognized for degradation by the proteolytic complexes called 
proteasomes. The 26S proteasome is considered the major proteolytic enzyme 
complex involved in intracellular protein degradation (18). 
Only a single E1 protein has been identified (15); while estimates for as 
many as 500 E2 targeting enzymes may exist for selection of individual proteins 
(14). A small number of E3s have been described (about 10) (18). In particular, 
two E3 ligases studied extensively in muscle are muscle RING-finger protein-1 
(MURF1), which targets myofibrilar protein degradation (5); and Atrogin1, which 
targets degradation of the transcription factor MyoD (17). 
E2s have specificity for the proteins, which they bind to; likewise, E3s also 
have specific binding sites for the E2 enzyme, the ubiquitin proteins they bind to, 
as well as the protein “targeted” for degradation. Accordingly, it is believed that 
E3s alone, or together with E2s, accounts for the specificity of the ubiquitin 
degradation process (18).  
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The 26S proteasome consists of a catalytic 20S and a regulatory 19S 
subunit, and is considered the major proteolytic enzyme complex involved in 
intracellular protein degradation (18). The catalytic 20S proteasome subunit is a 
large 600 kD particle, comprising up to 1% of cell proteins (18). These proteins 
have a barrel-shaped structure, consisting of four stacked rings, each comprised 
of subunits surrounding a central cavity (8). Inside are two rings composed of β 
subunits, which enclose a large central chamber containing the sites where the 
proteins are degraded; while the two outer rings are composed of α subunits 
(called PSMAs), which cover a small opening where protein substrates must 
enter (8). Seven different α and ten different β proteasome genes have been 
identified in mammals (22). 
To enter the proteasome, proteins must first be unfolded (8). Protein 
unfolding is handled by the regulatory 19S proteasome subunits (700 kD) (18), 
which are located on either end of the 20S proteasome. The 19S subunit 
provides specificity to proteolysis by binding ubiquinated substrates and 
catalyzing the degradation of polypeptides into the 20S subunit (8). There are six 
different ATPases located on the 19S complex suggesting that this process is 
ATP dependent (13). 
Once unfolded proteins enter the 20S subunit, they are “cut” multiple times 
into small peptides ranging from 3 to 25 residues in length, before the next 
protein is degraded (1). This progressive process of protein degradation is 
presumably designed to prevent partially digested proteins from accumulating 
and causing cell damage (18). Collectively, the specificity and energy 
requirements of the ubiquitin-protesome pathway make it ideal for selective 
regulation of the degradative process.  
Since discovery of the ubiquitin-protesome pathway, many studies have 
focused on its function and regulation – particularly, in states of muscle wasting. 
In this context, there is evidence suggesting that the essential amino acid Leu 
has anti-proteolytic effects, including attenuation of the ubiquitin-protesome 
pathway (30). For instance, Combaret et al. (7) demonstrated that Leu 
supplementation in elderly rats completely prevented the rise in ubiquitin-
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proteosome expression associated with age. Further, Baptista et al.(2) showed 
that Leu supplementation in rats with immobilized hind limbs, attenuated muscle 
loss, protein ubiquitination, and expression of E3 ligases MURF1 and Atrogin1.  
While these studies demonstrate a potential role of Leu in regulation of 
muscle protein degradation, virtually all research on Leu regulation of ubiquitin-
protoesome has been performed in vitro, or in muscle wasting models (9, 10), 
and is untested in healthy subjects under physiological conditions.  This study 
was designed to determine if feeding isonitrogenous protein sources with 
different Leu contents to healthy adult rats would differentially impact ubiquitin-
proteosome (protein degradation) outcomes; and if these outcomes are related to 
the meal responses of plasma Leu. This study of protein degradation was a 
component of a larger research project designed to evaluate if long-term 
consumption of higher Leu diets would result in sustained increases in MPS and 
changes in muscle mass. Results for MPS and changes in muscle mass have 
been reported previously for this study (23) and will be briefly summarized here 
for clarity.  
 
MATERIALS AND METHODS  
Animals. Thirty-nine male Sprague-Dawley rats (Harlan-Teklad, 
Indianapolis, IN) with a mean body weight of 270 ± 10 g, 9-11 weeks of age were 
housed individually in stainless steel wire-bottomed cages and maintained at 
24°C with 12 h reverse light cycle (light: 1900-0700 h) and free access to water. 
Rats were fed during the dark cycle time-periods and fasted during the light cycle 
periods. The animal protocol was approved by the University of Illinois 
Institutional Animal Care and Use Committee. 
Meal training protocol. Rats were trained to consume three meals each d 
using a modified AIN-93G diet  (54% of energy from carbohydrate, 16% protein, 
and 30% fat) (25). The meal pattern consisted of a 4 g breakfast meal consumed 
between 0700-0720 h, followed by free access to food between 1300-1400 h and 
1800-1900 h for an adaptation period of 6 d. Rats consumed ~18 g / d of diet 
during the adaptation period. After adaptation, rats were randomized to one of 
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four treatment diets containing either wheat gluten, egg protein isolate, or whey 
protein isolate as the protein source (n = 13 per group) with protein at 16% of 
energy. Wheat gluten was supplemented with lysine in order to meet National 
Research Council guidelines for maintenance and to approximate the lysine 
content of the whey isolate. The breakfast meals contained 46, 60, and 74 mg of 
leu, respectively, for the wheat, egg, and whey groups. The composition of the 
treatment diets is shown in Table 3.1.  
In order to optimize handling of energy and to normalize food intake 
between treatment groups, the treatment diets were fed at 80% of ad libitum 
intake (14 g/d). This was accomplished by feeding three daily meals of discrete 
amounts: a 4 g morning meal consumed between 0700-0720 h, followed by a 4 g 
afternoon meal 1300-1400 h and a 6 g evening meal from 1800-1900 h.  
Experimental Treatments. The animals consumed the treatment diets for 
11 weeks, at which point, rats were food deprived for 12 h and then either 
euthanized by decapitation (food deprived) (n = 5 per group) or fed their normal 4 
g morning meal (n = 8 per group). Ninety min after consumption of the meal, rats 
were euthanized by decapitation, and then blood and tissues were harvested. 
Gastrocnemius tissues were weighed prior to being snap frozen in liquid 
nitrogen. Tissues were then stored at -80°C until further analysis.  
Administration of metabolic tracer and tissue collection. MPS was 
measured in skeletal muscle using the flooding dose method (12). A 100% 
enriched L-[2H5]phenylalanine solution (150 mmol/L; Cambridge Isotopes, 
Andover, MA) was administered at 150 mmol/100 g body weight and injected via 
the tail vein (1 mL/100g body weight). After 10 min, animals were killed by 
decapitation, blood was collected in pre coated EDTA tubes, and hind limbs were 
quickly removed and immersed in an ice-water mixture. Gastrocnemius muscles 
were removed from cooled hind limbs, frozen in liquid N2, and stored at - 80°C.   
Measurement of MPS. Frozen muscle tissue was powdered in liquid 
nitrogen and protein was precipitated with cold (4°C) perchloric acid (30 g/L, 1 
mL/50 mg muscle tissue). The resulting supernatant and protein pellet were 
prepared for analysis by GC-MS as described previously (11, 19). The 
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enrichment of L-[2H5]phenylalanine in the muscle hydrolysate was measured by 
GC-MS using a 6890N GC and a 5973N mass detector (Agilent Technologies, 
Santa Clara, CA). The samples were analyzed under electron impact ionization 
and in splitless mode, and phenylethylamine ions at mass:charge ratio 106 (m + 
2) and 109 (m + 5) were monitored for enrichment analysis. 
The muscle supernatant was used to determine intracellular free 
phenylalanine enrichment. Free amino acids were purified by ion exchange resin 
solid-phase extraction using EZ:faast amino acid analysis sample testing kit 
(Phenomenex, Torrance, CA) and 2H5-phenylalanine enrichment was 
determined using a propyl chloroformate derivative with GC-MS by monitoring 
the ions at mass:charge ratio 206 (m) and 211 (m + 5) (21).   
MPS was determined using the rate of incorporation of L-
[2H5]phenylalanine into total mixed muscle protein as described previously (19). 
The time from injection of the metabolic tracer until tissue cooling was recorded 
as the actual time for L-[2H5]phenylalanine incorporation. MPS, defined as the 
percentage of tissue protein renewed each d, were calculated according to the 
formula: MPS = (Eb  x  100) / (Ea  x  t), where t is the time interval between 
injection and cooling of sampled tissue expressed in d and Eb and Ea are the 
enrichments of [2H5]Phe in hydrolyzed tissue protein and in muscle free amino 
acids, respectively. 
Plasma measurements. Plasma was obtained from trunk blood by 
centrifugation at 1800 X g; 10 min at 4°C. Plasma insulin concentrations were 
analyzed using a commercial RIA kit for rat insulin (Millipore, Billerica, MA). 
Plasma amino acid concentrations were determined by HPLC using a Waters 
2475 Fluorescence detector (26).  
Western blot analysis. Muscle supernatants were subjected to protein 
immunoblot analysis as previously described (12). Rabbit polyclonal antibodies 
were used for total PSMA2 (1:3,000 dilution) (a portion of the outer ring of the 
20S proteasome) (Cell Signaling, Boston, MA), total UBE2L3 (1:1,000 dilution) 
(an E2 ligase) (Cell Signaling, Boston, MA), Muscle RING-finger protein-1 
(MURF1) (1:2,000 dilution) (an E3 ligase) (Santa Cruz Biotechnology, Santa 
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Cruz, CA), Atrogin 1 (an E3 ligase) (1:500 dilution) (Santa Cruz Biotechnology, 
Santa Cruz, CA), and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(1:10,000 dilution) (Cell Signaling, Boston, MA). Anti-rabbit IgG, HRP-linked 
secondary antibody was purchased from Cell Signaling (1:2,000 dilution) 
(Boston, MA). 
Statistical analysis. Data are expressed as mean ± SEM. All variables 
were evaluated for normality and homogeneity of variance by Levene’s test. A 
one-way ANOVA was performed with the dietary treatment as the independent 
variable. When a significant effect was detected, differences among means were 
determined using an LSD post hoc test or a Games-Howell post hoc test when 
variances were not equal. The level of significance was set at P < 0.05. All 
analyses were performed using SPSS Version 15.0 (Chicago, IL).  
 
RESULTS 
The primary purpose of this study was to determine if feeding adult rats 
protein sources with different Leu contents would differentially regulate ubiquitin-
proteosome protein concentrations.  
After 11 weeks of feeding, rats were fed a breakfast meal providing ~30% 
of daily energy and with 16% of energy as protein. Plasma Leu increased in 
animals fed egg and whey proteins but not the wheat group. Other plasma amino 
acids varied among the groups largely in proportion to the amino acid content of 
the protein source. No essential amino acid was significantly below baseline 
post-prandially. Plasma insulin concentrations were above baseline at 90-min 
post meal, but did not differ between treatment groups (Table 3.2).   
Total PSMA2 was measured as an estimate of proteasome degradative 
capacity. Likewise, total UBE2L3 (an E2 ligase), MURF1 (an E3 ligase), and 
Atrogin 1 (an E3 ligase) proteins were measured as estimates of ubiquitin ligase 
degradative capacities.  
PSMA2 significantly decreased in rats fed egg and whey compared to 
animals fed wheat (P < 0.05) (Fig. 3.1a), suggesting decreased total proteasome 
degradative capacity in rats consuming higher Leu diets. Conversely, no 
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differences were detected in the ubiquitin ligases UBE2L3, MURF1, or atrogin1 
(Fig. 3.1b-d), suggesting that ligase capacity was not affected by treatments.  
A parallel purpose of this research was to determine if long-term 
consumption of higher Leu diets would result in sustained increases in MPS, and 
changes in muscle mass overtime (23). Briefly, post-prandial MPS was 
significantly greater in animals fed egg and whey than animals fed wheat, with no 
significant difference between the egg and whey groups (Fig. 3.2). 
Gastrocnemius muscle weights were also greater in animals fed egg and whey 
compared to animals fed wheat (Fig. 3.3).  
 
DISCUSSION 
The study examined if feeding isonitrogenous protein sources with 
different Leu contents to healthy adult rats would differentially impact ubiquitin-
proteosome (protein degradation) outcomes; and if these outcomes are related to 
the meal responses of plasma Leu. The primary finding was that total PSMA2 (a 
portion of the outer ring of the 20S proteasome) significantly decreased in rats 
fed egg and whey compared to animals fed wheat (Fig. 3.1a), suggesting 
decreased total proteasome degradative capacity in rats consuming higher Leu 
diets. However, there was no effect of diet treatment on any of the regulatory 
ubiquitin ligases, including E2 (UBE2L3), and E3 ligases (MURF1, or atrogin1) 
(Fig. 3.1b-d). These results suggest that protein quality within accepted dietary 
ranges has minimal regulatory effects on MPD in healthy adult rats.  
A parallel purpose of this research was to determine if long-term 
consumption of higher Leu diets would result in sustained increases in MPS, and 
changes in muscle mass overtime (23). Consistent with short-term feeding 
studies presented in Chapter II, after 11 weeks of meal feeding, animals fed egg 
and whey protein isolates had greater post-prandial increases in muscle protein 
synthesis (Fig. 3.2) and plasma Leu (Table 3.2). Furthermore, rats consuming 
whey or egg protein had larger gastrocnemius muscle weights than those 
consuming wheat protein (Fig. 3.3), and gastrocnemius weights correlated with 
post-prandial changes in MPS (r = 0.471, P < 0.01) and plasma Leu (r = 0.400, P 
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= 0.01). These findings demonstrate that short-term rises in post-prandial Leu are 
crucial for increasing MPS and contribute to long-term optimization of muscle 
mass.  
There is evidence suggesting that Leu has anti-proteolytic effects, 
including attenuation of the ubiquitin-protesome pathway (30); however, most of 
this research is in vitro, or in muscle wasting models (9, 10), and is untested in 
healthy subjects or under physiological conditions. Therefore, the present 
experiment sought to test these theories using a meal-feeding protocol with 
healthy adult rats. This study found significant effects of diet on PSMA2 (Fig. 
3.1a) but all measures of ubiquitin ligases were unchanged (Fig. 3.1b-d). These 
results suggest that the Leu effects on ubiquitin-proteosome pathways are more 
important in situations of muscle wasting, when this pathway becomes more 
active (2) (Fig. 3.4). While the decrease in PSMA2 by higher Leu diets may 
support greater muscle anabolism, collectively these results indicate that MPS is 
more responsive to this meal feeding protocol in healthy adults, than MPD. 
Accordingly, the changes in muscle mass observed overtime (Fig. 3.3) is likely 
due to the differences in MPS, rather than MPD (Fig. 3.2).  
 For the proteins used in this study only the wheat glutens lysine content 
was below the National Research Council (NRC) requirement for the adult rat 
(29). This specific requirement was corrected by supplementing the wheat gluten 
diet with lysine to the level of the concentration in whey protein (Table 3.3). All 
other EAA exceeded NRC guidelines. The unique regulatory role of Leu may in 
part explain the inconsistencies in comparison of optimal needs for Leu 
compared with current measures of minimum protein requirements for nitrogen 
balance or indispensable amino acid oxidation (IAAO) measurements. These 
standard measurements for protein requirement interpret postprandial increases 
in plasma amino acids as inefficient and excessive protein intake. While 
increased amino acid oxidation may reflect reduced efficiency of nitrogen 
retention of dietary protein and may provide an accurate representation of 
minimum requirements for an EAA such as lysine with no known metabolic 
signaling or regulatory roles, the extrapolation that protein intakes above the 
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minimum amount for short-term nitrogen balance are physiologically meaningless 
is not consistent with the regulatory role of Leu in MPS.   
In summary, this experiment supports the contention that Leu intakes 
above current requirements are beneficial for maximizing anabolic signaling in 
muscle tissue, and supports long term preservation of muscle mass. 
Furthermore, in this healthy adult rat-feeding model, ubiquitin-proteosome is less 
responsive to meal feeding than MPS. This finding is contrary to studies using 
muscle-wasting models, where MPD and ubiquitin-proteasome activity are 
typically increased, but significantly attenuated when Leu is added into the diet. 
These results suggest that Leus effects on ubiquitin-proteosome pathways are 
minimal for healthy adult rats consuming adequate diets. Thus, long-term 
changes in muscle mass observed in adult rats are likely due to the differences in 
MPS, rather than MPD.  
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FIGURES AND TABLES 
 
 
 
 
Fig. 3.1. Ubiquitin proteasome results for rats fed complete meals containing wheat, egg, or whey 
proteins for 11 weeks.  Differences reported for PSMA2 (outer ring of the 20S proteasome) (A), 
Atrogin1 (B), Muscle RING-finger protein-1 (MURF1) (C), and UBE2L3 (an E2 ligase) (D), with 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control. Data are means ± SEM; n = 13.  
Labeled means without a common letter differ, P < 0.05.  
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Fig. 3.2. Post-prandial rates of muscle protein synthesis (MPS) for rats fed complete meals 
containing wheat, egg, or whey proteins for 11 weeks.  Data are means ± SEM; n = 5-8. Labeled 
means without a common letter differ, P < 0.05.  
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Fig. 3.3. Gastrocnemius muscle weights (g) of rats fed complete meals containing wheat, egg, or 
whey proteins for 11 weeks.  Data are means ± SEM; n = 13.  Labeled means without a common 
letter differ, P < 0.05.  
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Fig. 3.4. Theoretical role of leucine regulation of ubiquitin-proteosome pathway. Evidence in 
muscle wasting populations show leucine supplementation can attenuate ubiquitin-proteosome 
expression; but research from this chapter showed minimal effects. UB (ubiquitin); MURF-1 
(muscle RING-finger protein-1).  
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Table 3.1. Composition of diets 
Component Wheat Diet Egg Diet Whey Diet 
Vital Wheat Gluten1 190.2 0.0 0.0 
Egg White Solids2 0.0 195.6 0.0 
Whey Protein Isolate3 0.0 0.0 188.8 
L-Lysine4 10.1 0.0 0.0 
Cornstarch 316.7 321.4 328.2 
Maltodextrin 134.1 134.1 134.1 
Sucrose 101.5 101.5 101.5 
Soybean Oil 140.9 140.9 140.9 
Cellulose (Fiber) 53.7 53.7 53.7 
Mineral Mix5 37.6 37.6 37.6 
Vitamin Mix5 10.7 10.7 10.7 
Choline Bitautrate 2.7 2.7 2.7 
Biotin6 (mg/kg) 0.0 16.0 0.0 
1Vital Wheat Gluten purchased from Honeyville Grain, Honeyville, UT.  83.4% protein, 7.6% 
carbohydrate, 9% other. 
2Egg White Solids purchased from Harlan-Teklad, Madison, WI.  87.8% Protein, 4.5% 
carbohydrate, 7.7% other. 
3Whey Protein Isolate provided by Perham, Perham, MN.  89.9% protein, 3.8% carbohydrate, 
6.3% other. 
4Vital Wheat Gluten supplemented with 6.3g L-lysine/100g protein to match Whey Protein Isolate.   
5Mineral and Vitamin supplements from Harlen-Teklad, Madison, WI. 
6Egg White Solids supplemented with 16.0 mg biotin/kg diet. 
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Table 3.2. Selected plasma essential amino acid, insulin, and glucose concentrations1 
 Baseline2 Wheat Egg Whey 
  µmol/L   
Leucine 84 ± 4.6c 78 ± 4.3c 146 ± 8.4b 192 ± 11.4a 
Isoleucine 56 ± 3.4d 50 ± 2.9d 121 ± 6.3b 144 ± 8.2a 
Valine 117 ± 8.2cd 95 ± 5.2d 143 ± 14.2a 248 ± 13.7b 
∑ BCAA 257 ± 16.0bc 223 ± 12.1c 562 ± 28.5a 584 ± 33.0a 
Lysine 510 ± 29.8ab 527 ± 23.8ab 495 ± 35.6ab 549 ± 29.3a 
Methionine 51 ± 2.9bc 46 ± 2.8bc 86 ± 6.8a 52 ± 5.2b 
Threonine 252 ± 13.7c 269 ± 30.4bc 357 ± 28.3ab 538 ± 51.2a 
Insulin pmol/L 140 ± 10.5b  178 ± 9.0a 184 ± 12.0a 170 ± 7.2a 
Glucose mg/dl 128 ± 15.4b 190 ± 37.7ab 236 ± 33.6a 171 ± 20.1ab 
1Values expressed as means ± SEM, n=5-8.  Labeled means without a common letter differ  
(P < 0.05).  
212 h food-deprived control.  
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Table 3.3.  Comparison of test diet amino acid compositions with NRC requirements1,2 
Amino Acid3  Wheat 
Diet 
Soy Diet Egg Diet Whey 
Diet 
NRC 
Requirement 
       
Phenyalanine/Tyrosine  11.5 17.0 16.8 10.7 1.9 
Histidine  3.1 4.2 3.9 3.4 0.8 
Isoleucine  5.1 8.1 9.0 10.5 3.1 
Leucine  11.5 13.6 14.9 18.5 1.8 
Lysine  15.4 10.7 11.0 15.4 1.1 
Methionine/Cysteine  6.5 4.4 13.9 7.6 2.3 
Threonine  4.4 6.5 7.6 10.9 1.8 
Tryptophan  2.2 2.0 2.7 2.7 0.5 
Valine  7.6 8.0 11.5 10.2 2.3 
1 From Nutrient Requirements of Laboratory Animals Fourth Revised Edition (29). 
2Values calculated for 300 g rat at maintenance 
3Amino acid values expressed as g/kg diet 
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CHAPTER IV:  
LEUCINE OR CARBOHYDRATE SUPPLEMENTATION REDUCES AMPK 
AND EEF2 PHOSPHORYLATION AND EXTENDS POSTPRANDIAL MUSCLE 
PROTEIN SYNTHESIS IN RATS1 
 
INTRODUCTION 
Muscle protein synthesis (MPS) is rapidly stimulated after consumption of 
a protein-containing meal, and is associated with activation of translation 
initiation by hormone and nutrient signals (29). Key regulatory points of 
translation initiation include assembly of the eukaryotic initiation factor 4F (eIF4F) 
complex and phosphorylation of the 70 kilodalton ribosomal protein S6 kinase 
(S6K1). Stimulation of these initiation factors is potentiated by insulin and the 
essential amino acid (EAA) leucine (Leu) (4, 5). After a meal, plasma 
concentrations of Leu and insulin trigger the activation of eIF4F and S6K1. 
Assembly of the eIF4F initiation complex involves phosphorylation of the 
inhibitory eIF4E binding protein-1 (4E-BP1), which releases the initiation factor 
eIF4E and allows it to bind with eIF4G. Binding of eIF4E with eIF4G promotes 
preparation of the mRNA for binding to the 43S pre-initiation complex. The 
postprandial rise in insulin activates the PI3K – Akt – mTORC1 (phosphoinositide 
3 kinase - protein kinase B - mammalian target of rapamycin complex 1) 
signaling cascade (4), while Leu acts downstream of Akt to stimulate mTORC1, 
through an as yet unidentified mechanism (12). Apart from the postprandial rise 
in plasma Leu, MPS does not appear to be limited by amino acids beyond that 
required to maintain basal levels (31), or by eIF2-mediated formation of the 43S 
pre-initiation complex (6, 24).  
While the initial translation initiation response shortly after a meal (< 2 h) 
has been well characterized, much less is known about what determines the 
duration of peak MPS following food intake. Two recent studies (8, 28) using 
                                                
1 Chapter IV is adapted from: Wilson GJ, Layman DK, Moulton CJ, Norton LE, Anthony TG, Proud CG, Rupassara 
SI, and Garlick PJ. Leucine or carbohydrate supplementation reduces AMPK and eEF2 phosphorylation and extends 
postprandial muscle protein synthesis in rats. Am J Physiol Endocrinol Metab. In-press: 2011. AJP grants the rights to the 
author(s) for any research article published in the Am J Physiol Endocrinol Metab to be reprinted in the author(s) thesis. 
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precisely timed meals containing intact proteins confirmed that the early 
postprandial rise of MPS (< 2 h) corresponded to increases in plasma insulin and 
Leu, as well as assembly of eIF4F and phosphorylation of S6K1 and 4E-BP1, but 
found that MPS declined by 3 h, despite continued elevations of plasma Leu, 
mTORC1 signaling, and translation initiation. This discordance between rates of 
MPS and initiation factor activity suggests that events other than eIF4F complex 
assembly and S6K1 phosphorylation determine the postprandial MPS response. 
In both experiments, the postprandial rise and fall of plasma insulin paralleled 
changes in MPS activity, suggesting that a decline in plasma insulin may limit 
MPS activity ~3 h after a meal.  
Consistent with the meal-feeding experiments, Bohé et al. (9) infused a 
complete amino acid mixture into adult volunteers for 6 h. The continuous 
infusion increased plasma amino acids 1.7-fold above basal levels and 
stimulated MPS for ~2 h, but MPS subsequently returned to baseline in spite of 
the continuous infusion of amino acids. Contrary to these findings, Wilson et al. 
(36) infused a large dose of Leu to neonatal pigs for 24 h, along with replacement 
amino acids to maintain basal levels, and found that MPS remained elevated for 
the entire infusion period. This discrepancy highlights the need for additional 
research to elucidate factors that determine the duration of the postprandial 
anabolic period.  
Potential explanations for the discordance between initiation signals and 
the duration of MPS after a meal include: 1) factors or steps within mRNA 
translation become refractory (unresponsive) to external stimuli, 2) reduced 
availability of amino acids, or 3) reduced signaling from insulin or other important 
stimuli. The purpose of this study was to determine if the postprandial period of 
muscle anabolism can be extended by supplemental doses of Leu, 
carbohydrates, or both; or if MPS becomes refractory to anabolic stimuli and 
requires a period of time to reset before it can be stimulated again. A better 
understanding of the relationship between MPS and the mechanisms leading to 
active mRNA translation in muscle may have implications for maintenance of 
lean tissue during weight loss or aging, for treatment of patients suffering trauma 
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or prolonged bed rest, as well as for acceleration of muscle development in 
athletes.  
 
MATERIALS AND METHODS 
Animals. Thirty-four Male Sprague-Dawley rats (269 ± 7 g, 9-11 weeks of 
age; Harlan-Teklad, Madison, WI) were housed individually and maintained at 
24°C with a 12 h reverse light cycle (light period: 1900-0700 h). Rats were fed 
during the dark period and had free access to water. The animal protocol and 
facilities were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of Illinois at Urbana-Champaign. 
Meal training protocol. Baseline diets provided 20%, 50%, and 30%, of 
energy from protein, carbohydrates, and fats, respectively (Table 4.1). Rats were 
trained to consume 3 meals/d consisting of 4 g meals at 0700 h and 1300 h and 
a 6 g meal at 1800 h. These meals provided 80% of daily ad libitum intake, which 
insured that energy intake was equal and that all food was consumed rapidly 
(within 20 min of introduction) (Fig. 4.1). This food restriction protocol does not 
alter development of lean tissue but reduces accumulation of body fat (20).  
Experimental Treatments. After 7 d of meal training, rats were food 
deprived for 12 h (1900 h - 0700 h), and then euthanized pre-meal at time 0 
(food-deprived), or at 90 or 180 min after the 4 g test meal. Based on previous 
research (28), the 90 min time point represented peak MPS activity, while the 
180 min time point reflected a period of time when mTORC1 signaling and 
initiation factor activity was elevated, but MPS returned to baseline values. At 
135 min after the test meal, rats were administered a 5 ml oral gavage of 
carbohydrates (CHO), leucine (Leu), CHO + Leu (LC), or a Sham (water) control 
(Fig. 4.1). 
The CHO supplement contained 2.63 g of carbohydrates (1.315 g glucose 
+ 1.315 g sucrose) in distilled water, which was slightly greater than the 
carbohydrate content of the 4 g meal (~2.2 g). The Leu supplement contained 
270 mg of Leu in distilled water, which was equivalent to the daily amount of Leu 
consumed by rats of this age and strain with free access to AIN-93 powdered diet 
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(Harlan-Teklad, Madison, WI) (19), and nearly three times the Leu content of the 
4 g meal (~100 mg). The LC supplement contained 2.36 g of carbohydrate (1.18 
g glucose + 1.18 g sucrose) and 270 mg of Leu in distilled water, which was 
isocaloric with the CHO gavage and isonitrogenous with the Leu gavage. The 
CHO and LC supplements supplied ~15% of daily energy intake for this age and 
strain of rat (19). The amounts and timing of the supplements were based on 
previous research that produced maximal Leu- and insulin-induced stimulations 
of translation initiation and MPS 45 min after oral gavage (2, 3, 6, 12).  
Administration of metabolic tracer and sample collection. MPS was 
measured in skeletal muscle using the flooding dose method (18). A 100% 
enriched L-[2H5]phenylalanine solution (150 mmol/L; Cambridge Isotopes, 
Andover, MA) was administered at 150 mmol/100 g body weight and injected via 
tail vein (1 mL/100g body weight). After 10 min, animals were euthanized by 
decapitation, blood was collected in pre-coated EDTA tubes, and hind limbs were 
quickly removed and immersed in an ice-water mixture. Gastrocnemius muscles 
were removed from cooled hind limbs, frozen in liquid N2, and stored at -80°C.  
Determination of MPS. Frozen muscle tissue was powdered in liquid 
nitrogen and protein was precipitated with cold (4°C) perchloric acid (30 g/L, 1 
mL/50 mg muscle tissue). The resulting supernatant and protein pellet were 
prepared for MPS analysis as described previously (16, 26). The enrichment of 
L-[2H5]phenylalanine in the muscle hydrolysate was measured by GC-MS using 
a 6890N GC and a 5973N mass detector (Agilent Technologies, Santa Clara, 
CA). Samples were analyzed under electron impact ionization in splitless mode 
and the mass:charge ratio of phenylethylamine ions at 106 (m + 2) and 109 (m + 
5) were monitored for enrichment. 
The muscle supernatant was used to determine intracellular free 
phenylalanine enrichment. Free amino acids were purified by ion exchange resin 
solid-phase extraction using EZ : faast amino acid analysis sample testing kit 
(Phenomenex, Torrance, CA) and 2H5-phenylalanine enrichment was 
determined using a propyl chloroformate derivative with GC-MS by monitoring 
the ions at mass:charge ratio 206 (m) and 211 (m + 5) (27).  
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MPS was assessed from the rate of incorporation of L-[2H5]phenylalanine 
into total mixed muscle protein as described previously (26). The time from 
injection of the tracer until tissue cooling was recorded as the actual time for L-
[2H5] phenylalanine incorporation. MPS, defined as the percentage of tissue 
protein renewed each day, were calculated according to the formula: MPS = (Eb 
x 100) / (Ea x t), where t is the time interval between injection and cooling of 
sampled tissue expressed in days and Eb and Ea are the enrichments of 
[2H5]Phe in hydrolyzed tissue protein and in muscle free amino acids, 
respectively. 
Plasma measurements. Plasma was obtained from trunk blood by 
centrifugation at 1800 x g for 10 min at 4°C. Plasma insulin concentrations were 
analyzed using a commercial RIA kit for rat insulin (Millipore, Billerica, MA). 
Plasma amino acid concentrations were determined by HPLC using a Waters 
2475 Fluorescence detector (Milford, MA) (30).  
Western blot analysis. Muscle supernatants were subjected to protein 
immunoblot analysis as previously described (12). Rabbit polyclonal antibodies 
were used for total and phospho-S6K1 (Thr389) (1:1,000 dilution), total and 
phospho-4E-BP1 (Thr37/46) (1:1,000 dilution), total and phospho-eEF2 (Thr56) 
(1:25,000 dilution), total and phospho-AMPKα (Thr172) (adenosine 
monophosphate-activated protein kinase) (1:2,000 dilution), total and phospho-
ACC (Ser79) (acetyl-CoA carboxylase) (1:2,000 dilution), total and phospho-Akt 
(Ser473) (1:1,000 dilution), total and phospho-eIF2α (Ser51) (eukaryotic initiation 
factor 2α) (1:250 dilution), as well as total and phospho-eIF2Bε (phospho-serine 
535) (eukaryotic initiation factor 2B epsilon) (Invitrogen, Camarillo, CA) (1:1,000 
dilution). All primary antibodies used were purchased from Cell Signaling 
(Boston, MA), unless stated otherwise. Anti-rabbit IgG, HRP-linked secondary 
antibody was also purchased from Cell Signaling (1:2,000 dilution) (Boston, MA).  
Nucleotide analysis. Adenosine 5'-monophosphate (AMP) and adenosine 
5'-triphosphate (ATP) were determined by HPLC analysis as described in a 
technical note CN-039 by Phenomenex (Torrance, CA). Briefly, frozen 
gastrocnemius muscle was ground under liquid nitrogen and 50 mg of sample 
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was combined with 1 ml of MeOH in water (25:75) and vortexed. This sample 
was centrifuged at 10,000 RPM at 4 °C for 5 min and the supernatant extracted. 
The supernatant was dried and then reconstituted in phosphate buffered saline 
(PBS). The sample was then passed through a Strata X-AW 33u Polymeric 
Weak Anion Solid Phase Extraction Sorbent (Phenomenex, Torrance, CA). Ten 
microliter aliquots of the final muscle extract were injected onto the HPLC using a 
Phenomenex Gemini 5u C18 110A Column 150 x 4.6 mm with temperature set at 
°25. A single mobile phase was used at a flow rate of 1 ml / min with 25% 
acetonitrile / 10mM KH2PO4 pH 7.0 (pH was adjusted with potassium hydroxide 
(KOH) / 5mM tetrabutylammonium chloride (TBAC). Nucleotide peaks were 
measured by UV detection at wavelength 260 nm. Peaks were identified by 
comparison with external standards (Sigma-Aldrich, St. Louis, MO).  
Statistical analysis. All data were analyzed by SPSS 15.0 software 
package for Windows (Chicago, IL). A one-way ANOVA was performed with the 
postprandial times and oral gavage treatments as the independent variables. 
When a significant overall effect was detected, differences among individual 
means were assessed using LSD post hoc test. For plasma amino acids, a one-
way ANOVA was performed for meal effects (0, 90, and 180 min) and 
supplement effects (Sham, CHO, Leu, and LC at 180 min). Correlations were 
determined by linear regression (Pearson correlation). The level of significance 
was set at P < 0.05 for all statistical tests. Values are presented as means ± 
SEM. 
 
RESULTS 
This experiment evaluated the potential for supplemental Leu or 
carbohydrates to extend the peak MPS response after a meal. Consistent with 
previous research (28), MPS increased at 90 min after a 4 g test meal but then 
returned to food-deprived values at 180 min (Sham). Supplementation with Leu, 
CHO, or LC 135 min after the test meal significantly increased MPS at 180 min 
above Sham rats and equal to meal-fed rats at 90 min (Fig. 4.2).  
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To understand the mechanisms explaining these findings, changes in 
plasma amino acid concentrations were first examined. As expected, plasma Leu 
and EAAs increased 90 min after the meal and remained elevated at 180 min 
(Table 4.2).  
Administering the Leu supplements at 135 min elevated plasma Leu at 
180 min; however, Leu and LC also depressed plasma isoleucine and valine 
below sham values (Fig. 4.3). Likewise, the CHO gavage lowered plasma 
branched-chain amino acids (BCAA; Leu, isoleucine, and valine) below sham 
levels. The supplements had no effect on levels of other measured plasma EAA, 
including methionine, threonine, and lysine, relative to Sham control (Fig. 4.3).  
Phosphorylation of S6K1 (Thr389) was measured as a marker of 
mTORC1 signaling. Consistent with previous reports (8, 28), relative 
phosphorylation of S6K1 (Thr389) in muscle increased at 90 min (P < 0.05) and 
remain elevated at 180 min (sham control) compared with food deprived rats 
(time 0) (P < 0.05) (Fig. 4.4). Likewise, supplemental treatments maintained 
S6K1 activation at 180 min. From 0 to 90 min, there was a significant correlation 
between S6K1 phosphorylation and MPS (r = 0.843, P < 0.05). However, from 90 
to 180 min after the meal, no statistical correlation was present (r = 0.163, P > 
0.05). Similar results were seen for phospho-4E-BP1 (Thr37/46) (Fig. 4.4).  
To evaluate other steps in translation initiation, phosphorylation of 
regulatory sites in eIF2α (Ser51) and eIF2Bε (Ser535) were examined as 
markers of eIF2 activation. No changes in phosphorylation of either of these 
proteins were found (data not shown). 
Consistent with earlier publications (8, 28) plasma insulin rose at 90 min 
post-meal and returned to food-deprived (time 0) values at 180 min (Sham) (Fig. 
4.5). The CHO and LC supplements maintained elevated insulin at 180 min, 
while the Leu supplement was not different from the Sham group at 180 min. 
Phosphorylation of Akt (Ser473) was measured as an indicator of insulin 
signaling but no differences in Akt activation were detected among the groups at 
180 min (data not shown).  
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Since the decline in MPS at 180 min post-meal (Sham) was not related to 
changes in essential amino acids, plasma insulin, or phosphorylation of S6K1, 
eIF2α, or eIF2Bε, the phosphorylation of eEF2 (Thr56) was measured, for an 
indication of translation elongation activity. After the meal, eEF2 phosphorylation 
decreased from 0 to 90 min reflecting activation of elongation for MPS, but 
returned to food-deprived (time 0) values at 180 min post-meal (Sham control) 
consistent with inhibition of elongation (Fig. 4.6) and the decline in MPS. All three 
supplements (Leu, CHO, and LC) reduced eEF2 phosphorylation at 180 min 
relative to Sham control. Across all treatment groups, there was an inverse 
association between phospho-eEF2 and MPS (r = - 0.500, P < 0.05). 
Phosphorylation of AMPKα (Thr172) and its substrate ACC (Ser79) and 
the nucleotide ratio of AMP/ATP were measured as indicators of cellular energy 
status (Fig. 4.7). In meal-fed rats, phosphorylation of muscle AMPKα and ACC 
(21) declined at 90 min as compared to food deprived rats reflecting increased 
energy availability, but increased at 180 min reflecting decreased energy 
availability. All three of the supplemental treatments maintained reduced 
phospho-AMPKα and ACC to levels similar to the 90 min post-meal values. 
Similarly to changes in phospho-AMPKα and ACC, the ratio of AMP/ATP 
(allosteric regulator of AMPK (22) and a direct measure of cellular energy status) 
declined at 90 min post-meal but increased above food deprived values at 180 
min. Each of the supplements served to maintain a reduced ratio of AMP/ATP at 
180 min, consistent with the behaviors of AMPKα and ACC.  
 
DISCUSSION 
This study demonstrates that Leu or CHO supplements provided ~2 h 
after consumption of a complete meal can extend the postprandial anabolic 
period of MPS (Fig. 4.2). Further, the findings of this study suggest that the 
incongruity between MPS and mTORC1 signaling 180 min after a meal is 
associated with activation of AMPK (Fig. 4.7) and reduced translation elongation 
activity (Fig. 4.6). These data suggest that temporal changes in skeletal muscle 
energy state following meal feeding influence the period of muscle anabolism. 
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Further, the energy status of muscle can be enhanced by post-meal nutrition 
supplements to extend the period of muscle anabolism.  
Translation initiation is a critical regulatory step for stimulating the rise in 
MPS after a meal, and is activated by nutrient signals derived from changes in 
plasma insulin and Leu and propagated through the PI3K – Akt – mTORC1 
signaling cascade (4). Triggering of initiation and maximum MPS activity occurs 
within 30 to 60 min following administration of free Leu (6) and 60 to 90 min 
following ingestion of intact proteins (8, 28). Two recent studies (8, 28) using 
precisely timed meals containing intact proteins confirmed that the early 
postprandial rise of MPS (< 2 hr) corresponded to increases in plasma insulin 
and Leu, as well as phosphorylation of S6K1 and 4E-BP1 and assembly of the 
eIF4F initiation complex, but found that MPS declined after 3 h, despite 
continued elevations of plasma Leu, mTORC1 signaling, and translation 
initiation. The present study is consistent with these reports, finding a 
postprandial rise in plasma Leu and significant correlation between phospho-
S6K1 and MPS (r = .843, P < 0.05) from 0 to 90 min after the test meal (Fig. 4.4). 
However, from 90-180 min post-meal, the correlation between phospho-S6K1 
and MPS disappears (r = .163, P > 0.05) (Fig. 4.4). Likewise, similar results were 
found for phospho-4E-BP1 (Fig. 4.4). Furthermore, no changes in the 
phosphorylation states of eIF2α or eIF2Bε were found, suggesting that eIF2 is 
unlikely to be a regulatory factor for postprandial changes in MPS. Collectively, 
these findings are consistent with the hypothesis that translation initiation 
signaling via mTORC1 facilitates the initial rise in MPS after a meal; however, 
factors in addition to translation initiation are required to sustain peak MPS 180 
min after a meal (8,28).  
Potential explanations for the discordance between initiation signals and 
the postprandial duration of MPS include: 1) factors or steps within mRNA 
translation become refractory (unresponsive) to external stimuli, 2) reduced 
availability of amino acids, or 3) reduced signaling from insulin or other important 
signals. In the present study, all three nutrient supplements were able to extend 
the duration of peak MPS demonstrating that mRNA translation is not refractory 
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to anabolic stimuli, but rather limited by one or more regulatory factors. Additional 
measures were taken determine what factors limited the postprandial duration of 
MPS, and why either Leu, or CHO supplements overcame these limitation(s).  
Results showed that plasma essential amino acids remained elevated at 
180 min after the meal (sham control) relative to the 90 min time point and that 
Leu or CHO treatments were sufficient to extend MPS without providing 
additional amino acids (Table 4.2) establishing that availability of essential amino 
acids was not a primary limitation during the decline in MPS.  
Likewise, insulin does not appear to be a critical factor in extending MPS 
(Fig. 4.5). As expected, the carbohydrate treatments (CHO and LC) increased 
plasma insulin concentration at 180 min compared to the sham control, however 
the Leu treatment – which prolonged the duration of MPS at 180 min – did not 
maintain elevated insulin concentration at 180 min. There were no differences 
between groups in phosphorylation of the insulin-signaling target Akt at 180 min 
(data not shown). However, research has previously shown that peak insulin and 
Akt responses occur 30 min after a complete meal (14), and < 20 min after 
administration of these supplements (4). Therefore, the time-point measurements 
used in this study most likely missed peak insulin and Akt responses. Thus, the 
influence of insulin signaling on the duration of MPS remains unresolved.  
Another possible determinant of the post-meal reduction in MPS is a 
decrease in translation elongation. In this experiment, phosphorylation of eEF2 
(Thr56) was used as an indicator for translation elongation activity. Results 
showed increased phosphorylation of eEF2 in the sham control, indicating 
inhibition of eEF2 at 180 min after the test meal (Fig. 4.6). Conversely, 
phosphorylation of eEF2 was reduced by each of the supplements at 180 min 
consistent with sustained elevation of MPS after the meal.  
Proud and colleagues have shown inhibition of eEF2 and protein 
synthesis in response to mild energy deficits is associated with activation of 
AMPK, which stimulates the regulatory kinase eukaryotic elongation factor 2 
kinase (eEF2K) to subsequently phosphorylate (inhibit) eEF2 (11, 23). The ability 
of AMPK to respond to changes in AMP/ATP – with AMP stimulating AMPK, and 
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ATP inhibiting it – allows this kinase to be an effective cellular energy sensor 
(22). Measurements of AMPKα phosphorylation, the ratio of AMP/ATP, and 
phosphorylation of ACC were taken to determine if energy status of muscle could 
be a limiting factor for MPS 180 min after a meal (Fig. 4.7). Consistent with the 
energy hypothesis, each of the biomarkers for cellular energy status reflected 
energy stress in the cell and produced a pattern of change nearly identical with 
that observed for eEF2 (Fig. 4.6). Further, there was a significant inverse 
correlation across treatments between MPS and AMPKα phosphorylation (r = -
0.581, P < 0.05). Collectively, these results suggest that energy is a likely 
determinate of the duration of postprandial MPS, and that eEF2 is the regulatory 
step responding to energy status.  
When considering the upstream regulators of translation initiation and 
elongation, there appears to be a paradox in these signals. Indeed, AMPK and 
mTORC1 are both regulators of translation initiation and elongation, but act in 
opposing ways – with AMPK inhibiting translation initiation (7) and elongation 
(10), and mTORC1 stimulating these processes (33). The findings that both 
mTORC1 (8,28) and AMPK (Fig. 4.7) are activated during the postprandial 
decline in MPS suggests that AMPK and energy become the dominant signals. 
Further, the finding that eEF2, a key regulator of translation elongation, is 
inhibited coinciding with down-regulation of MPS, indicates that the AMPK 
inhibitory effect on eEF2 overrides the stimulatory effects of mTORC1.  
Support for this hierarchal form of regulation is provided from research by 
Proud and colleagues (10, 11, 23, 25, 32). In a variety of cell lines (10, 23, 25, 
32) these authors have shown that under mild energy deficits, AMPK activation 
results in strong and rapid inhibition of eEF2 and translation elongation, with no 
corresponding changes in phosphorylation of proteins involved in the initiation 
stages of mRNA translation, including eIF2, p70S6K1, 4E-BP1, and assembly of 
the eIF4F initiation complex. Contrary to these findings, Dennis et al. (13) 
demonstrated inhibition of mTORC1 signaling using higher concentrations of the 
AMPK agonist 2-DOG (10 fold greater than Proud and colleagues) (2-
deoxyglucose). Likewise, Williamson et al. (35) reported inhibition of mTORC1 
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signaling by AMPK using higher levels of AICAR (double the amount of Proud 
and colleagues) (5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside). 
Overall, the current study and the published reports by Proud and colleagues 
suggest that the physiological regulation of cellular energy status by AMPK 
exerts a dominant effect over the anabolic stimulation of MPS by mTORC1 .  
Considering that protein turnover is a metabolically costly process, 
accounting for approximately one quarter of resting energy expenditure (34), it is 
logical that a cell would suppress protein synthesis activity during an energy 
deficit to preserve critical functions. Furthermore, when considering that 
translation elongation accounts for the majority (> 99%) of the energy used for 
polypeptide assembly (10, 11, 29), it appears logical that the cell would regulate 
translation elongation to protect energy status.  
The finding that the large Leu supplement was able to decrease AMPKα 
phosphorylation is consistent with the work from Du et al. (15), who showed that 
Leu treatment in C2C12 myoblast cells resulted in a 36% decrease in the 
AMP/ATP ratio, a 28% reduction in phospho AMPKα, and a 43% reduction in 
AMPK activity. Leu can provide energy (ATP) to muscle by conversion to 
ketoisocaproate (KIC) and its subsequent oxidation via the TCA cycle. Increased 
KIC levels in skeletal muscle have also been shown to increase oxidation of all 
three BCAA (Leu isoleucine, and valine) by allosteric activation of branched-
chain α-keto-acid dehydrogenase (1, 17). In support of the hypothesis that Leu 
increased BCAA oxidation, the Leu-containing supplements in the present 
experiment reduced isoleucine and valine concentrations by 50-150%, while 
other plasma EAAs remained unchanged relative to sham control (Fig. 4.3).  
In summary, intake of a Leu or CHO supplements ~2 h after consumption 
of a complete meal can extend the duration of the postprandial rise in MPS. 
Further, the incongruity between MPS and mTORC1 signaling at 180 min after 
the meal does not reflect a refractory period or decreased sensitivity to anabolic 
stimuli, but rather, an increase in AMPK activity and a decrease in translation 
elongation activity. Improved understanding of factors that regulate the duration 
of MPS may have implications for maintenance of lean tissue during weight loss 
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or aging, for treatment of patients suffering trauma or prolonged bed rest, as well 
as for acceleration of muscle development in athletes. As such, the roles of eEF2 
and AMPK in regulation of postprandial MPS warrant further investigation.  
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FIGURES AND TABLES 
 
Fig. 4.1. Experimental design and timeline. Treatment groups were intubated at 135 min after the 
meal with water (sham), carbohydrates (CHO), leucine (Leu), or combination of CHO + Leu (LC). 
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Fig. 4.2. Postprandial changes for muscle protein synthesis (MPS). Treatment groups were 
intubated at 135 min after the meal with water (sham), carbohydrates (CHO), leucine (Leu), or 
combination of CHO + Leu (LC). Data are means ± SEM; n = 4-6. Means without a common letter 
differ, (P < 0.05).  
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Fig. 4.3. Percent difference of selected plasma amino acid concentrations from control (sham 
treatment) for each supplement. Data are means ± SEM; n = 6. Treatment groups were intubated 
at 135 min after the meal with water (sham), carbohydrates (CHO), leucine (Leu), or combination 
of CHO + Leu (LC), with measurements taken 180 min after the meal. Means without a common 
letter differ, (P < 0.05). * Indicates that amino acid differs from sham (P < 0.05).  
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Fig. 4.4. Postprandial changes in the relative phosphorylation state of ribosomal S6 protein 
kinase 1 (phospho-S6K1 (Thr389) / total-S6K1) and eIF4E binding protein-1 (phospho-4E-BP1 
(Thr37/46) / total 4E-BP1). Treatment groups were intubated at 135 min after the meal with water 
(sham), carbohydrates (CHO), leucine (Leu), or combination of CHO + Leu (LC). Data are means 
± SEM; n = 4-6. Means without a common letter differ, (P < 0.05).  
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Fig. 4.5. Postprandial changes in plasma insulin. Treatment groups were intubated at 135 min 
after the meal with water (sham), carbohydrates (CHO), leucine (Leu), or combination of CHO + 
Leu (LC). Data are means ± SEM; n = 4-6. Means without a common letter differ, (P < 0.05).  
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Fig. 4.6. Postprandial changes in the relative phosphorylation state of eukaryotic elongation factor 
2 (phospho-eEF2 (Thr56) / total eEF2). Treatment groups were intubated at 135 min after the 
meal with water (sham), carbohydrates (CHO), leucine (Leu), or combination of CHO + Leu (LC). 
Data are means ± SEM; n = 4-6. Means without a common letter differ, (P < 0.05).  
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Fig. 4.7. Postprandial changes in the relative phosphorylation states of adenosine 
monophosphate-activated protein kinase alpha (phospho-AMPKα (Thr172) / total AMPKα), 
acetyl-CoA carboxylase (phospho-ACC (Ser79) / total ACC), and nucleotide ratio of AMP/ATP 
(adenosine 5′-monophosphate / adenosine 5′-triphosphate). Treatment groups were intubated at 
135 min after the meal with water (sham), carbohydrates (CHO), leucine (Leu), or combination of 
CHO + Leu (LC). Data are expressed as percent change from fasted (time 0) values. Data are 
means ± SEM; n = 4-6. Means without a common letter differ, (P < 0.05).  
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Table 4.1. Meal composition  
________________________________ 
Components     g/kg  
________________________________ 
 
Whey Protein Isolate1  1228.0 
Corn starch   290.0 
Maltodextrin   134.1 
Sucrose   101.5 
Soybean oil   140.9 
Cellulose   53.7 
Mineral Mix2   37.6 
Vitamin Mix2   10.7 
Choline bitautrate  2.7 
TBHQ3    0.014 
_________________________________ 
 
1Whey protein provided by Perham, Perham, MN.  
(89.9% protein, 3.8% carbohydrate, 6.3% other).  
2Purchased from Harlen-Teklad, Madison, WI.  
3TBHQ, tertiary butylhydroquinone. 
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Table 4.2. Postprandial concentrations of selected essential amino acids in plasma following meal 
consumption 
__________________________________________________________   
Time (min)        01     90    180      
__________________________________________________________  
     µmol/L  
Leucine   200±18b 297±31a 312±19a 
Isoleucine  100±11b 150±16a 148±12a 
Valine   171±19a 221±25a 243±13a 
Lysine   569±33b 724±61a 595±38ab 
Methionine    72±8a     88±6a    88±5a 
Threonine  799±96a 982±71a 993±68a  
__________________________________________________________ 
 
Values expressed as means ± SEM; n = 4-6.  
Means without a common letter differ, (P < 0.05).  
112 h food deprived controls 
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CHAPTER V:  
DOSE AND TIME DEPENDENT EFFECTS OF LEUCINE OR 
CARBOHYDRATE SUPPLEMENTS TO REDUCE AMPK AND EEF2 
PHOSPHORYLATION AND EXTEND POSTPRANDIAL MUSCLE PROTEIN 
SYNTHESIS IN RATS 
 
INTRODUCTION 
  Studies investigating nutritional regulation of muscle protein synthesis 
(MPS) have shown that consumption of the essential amino acid leucine (Leu) is 
a key factor determining the anabolic response of MPS to a meal (15). Most 
studies investigating Leu stimulated protein synthesis have focused on early 
postprandial responses (< 2 h); however, much less is known about what 
determines the duration of peak MPS following food intake. In Chapter IV, 
research investigating the postprandial anabolic period was discussed (29). 
Using an adult rat-feeding model, it was demonstrated that MPS increased 
rapidly after a breakfast meal but declined by 180 min in spite of continued 
elevations of plasma amino acids, plasma Leu, and translation initiation signals. 
The decline in MPS was inversely associated with the phosphorylation states of 
translation elongation factor 2 (eEF2), the “cellular energy sensor” adenosine 
monophosphate-activated protein kinase alpha (AMPKα), and the AMPKα 
substrate acetyl-CoA carboxylase (ACC) and with increases in the ratio of AMP / 
ATP. Supplementation with a large dose of Leu (270 mg, triple the amount of the 
breakfast meal), carbohydrates (2.63 g, slightly more than the breakfast meal), or 
a combination of both 135 min after the meal were all able to maintain peak rates 
of MPS through 180 min post-meal, and prevent rises in phosphorylation of 
eEF2, AMPKα, and ACC, as well as the ratio of AMP / ATP. These findings are 
consistent with the proposed mechanism that the cell regulates protein synthesis 
during mild energy deficits through activation of AMPKα which stimulates the 
regulatory kinase eukaryotic elongation factor 2 kinase (eEF2K) to subsequently 
phosphorylate (inhibit) eEF2 (9, 20). 
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  Leu and carbohydrates are both energy substrates in skeletal muscle but 
would be expected to have different impacts on cellular energy and signaling. 
Yet, previous research (29) demonstrated that both substrates were effective at 
increasing energy and extending post-prandial MPS. Two limitations of the initial 
study were that maximum oral doses of the supplements were given and only 
one time point was measured. Therefore, the present experiments were 
designed to extend the initial findings by examining the impact of Leu and 
carbohydrate supplements on MPS, cellular energy status, and signaling 
elements using multiple doses and time-points.  
 
MATERIALS AND METHODS 
Animals. Ninety-two male Sprague-Dawley rats (256 ± 8 g, 9-11 weeks of 
age; Harlan-Teklad, Madison, WI) were housed individually and maintained at 
24°C with a 12 h reverse light cycle (light period: 1900-0700 h). Rats were fed 
during the dark period and had free access to water. The animal protocol and 
facilities were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of Illinois at Urbana-Champaign.  
Meal training protocol. Baseline diets provided 20%, 50%, and 30%, of 
energy from protein, carbohydrates, and fats, respectively. Rats were trained to 
consume 3 meals/d consisting of 4 g meals at 0700 h and 1300 h and a 6 g meal 
at 1800 h. These meals provided 80% of daily ad libitum intake, which insured 
that energy intake was equal and that all food was consumed rapidly (within 20 
min of feeding). This food restriction protocol does not alter development of lean 
tissue but reduces accumulation of body fat (18). 
 Experiment 1 evaluated specific responses of MPS, AMPK, and eEF2 to 
four energy levels of oral supplements of carbohydrates and BCAA. After 7 d of 
meal training, rats were food deprived for 12 h (1900 h - 0700 h), and then 
euthanized pre-meal at time 0 (food-deprived), or at 90 or 180 min after the 4 g 
control meal. Based on previous research (25), the 90 min time point represented 
peak MPS activity, while the 180 min time point reflected a period of time when 
MPS declined. At 135 min post-meal, rats were gavaged with 270 mg Leu 
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(Leu270), 80 mg Leu, 40 mg isoleucine and 40 mg of valine (Leu80), 2.63 g 
carbohydrates (CHO2.6), 1 g carbohydrates (CHO1.0), or water (Sham control). 
The CHO2.6 supplement contained 2.63 g of carbohydrates (1.315 g 
glucose + 1.315 g sucrose) in distilled water, which was similar to the 
carbohydrate content of the 4 g control meal (~2.2 g). The CHO1.0 supplement 
contained 1 g of carbohydrates (0.5 g glucose + 0.5 g sucrose) in distilled water. 
The Leu270 supplement contained 270 mg of Leu in distilled water, which is 
equivalent to the daily amount of Leu consumed by rats of this age and strain 
with free access to AIN-93 diet (Harlan-Teklad, Madison, WI) (17). The Leu80 
supplement contained 80 mg of Leu, 40 mg of isoleucine and 40 mg of valine, 
which approximated the amount of branched-chain amino acids (BCAA) in the 
control meal.  
The amounts and timing of the supplements was based on previous 
research that produced maximal Leu and insulin-induced stimulations of 
translation initiation and MPS 45 min after oral gavage in the fasted state (3, 4, 6, 
10). The addition of isoleucine and valine to the Leu80 supplement served to 
balance the BCAA formula (Leu80) to determine how this compared to Leu270, 
which lacked isoleucine and valine. 
Experiment 2 evaluated supplement effects on MPS, AMPK, and eEF2 
responses at multiple time points after oral supplements to determine the 
duration of signaling responses. After 7 d of meal training, rats were food 
deprived for 12 h (1900 h - 0700 h), and fed the 4 g control meal. At 135 min 
after the meal, rats were administered a 5 ml oral gavage of CHO1.0, Leu80, or 
water (Sham), as previously described. Rats were sacrificed at 3 time points: 20, 
45, and 120 min post-gavage (155, 180, and 255 min post-meal, respectively). 
These time-points were selected based on previous experiments, and designed 
to observe maximal anabolic signaling and MPS responses 20-45 min after oral 
gavage, and a decline in MPS and anabolic signaling 120 min after oral at oral 
bolus (3, 4, 6, 10).  
Administration of metabolic tracer and sample collection. MPS was 
measured in skeletal muscle using the flooding dose method (16). A 100% 
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enriched L-[2H5]phenylalanine solution (150 mmol/L; Cambridge Isotopes, 
Andover, MA) was administered at 150 mmol/100 g body weight and injected via 
tail vein (1 mL/100g body weight). After 10 min, animals were euthanized by 
decapitation, blood was collected in pre-coated EDTA tubes, and hind limbs were 
quickly removed and immersed in an ice-water mixture. Gastrocnemius muscles 
were removed from cooled hind limbs, frozen in liquid N2, and stored at -80°C.  
Determination of MPS. Frozen muscle tissue was powdered in liquid 
nitrogen and protein was precipitated with cold (4°C) perchloric acid (30 g/L, 1 
mL/50 mg muscle tissue). The resulting supernatant and protein pellet were 
prepared for MPS analysis as described previously (13, 22). The enrichment of 
L-[2H5]phenylalanine in the muscle hydrolysate was measured by GC-MS using 
a 6890N GC and a 5973N mass detector (Agilent Technologies, Santa Clara, 
CA). Samples were analyzed under electron impact ionization in splitless mode 
and the mass:charge ratio of phenylethylamine ions at 106 (m + 2) and 109 (m + 
5) were monitored for enrichment. 
The muscle supernatant was used to determine intracellular free 
phenylalanine enrichment. Free amino acids were purified by ion exchange resin 
solid-phase extraction using EZ : faast amino acid analysis sample testing kit 
(Phenomenex, Torrance, CA) and 2H5-phenylalanine enrichment was 
determined using a propyl chloroformate derivative with GC-MS by monitoring 
the ions at mass:charge ratio 206 (m) and 211 (m + 5) (23).  
MPS was assessed from the rate of incorporation of L-[2H5]phenylalanine 
into total mixed muscle protein as described previously (22). The time from 
injection of the tracer until tissue cooling was recorded as the actual time for L-
[2H5] phenylalanine incorporation. MPS, defined as the percentage of tissue 
protein renewed each day, were calculated according to the formula: MPS = (Eb 
x 100) / (Ea x t), where t is the time interval between injection and cooling of 
sampled tissue expressed in days and Eb and Ea are the enrichments of 
[2H5]Phe in hydrolyzed tissue protein and in muscle free amino acids, 
respectively. 
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Plasma measurements. Plasma was obtained from trunk blood by 
centrifugation at 1800 x g for 10 min at 4°C. Plasma insulin concentrations were 
analyzed using a commercial RIA kit for rat insulin (Millipore, Billerica, MA). 
Plasma amino acid concentrations were determined by HPLC using a Waters 
2475 Fluorescence detector (Milford, MA) (27).  
Western blot analysis. Muscle supernatants were subjected to protein 
immunoblot analysis as previously described (10). Rabbit polyclonal antibodies 
were used for total and phospho-AMPKα (Thr172) (1:2,000 dilution) (adenosine 
monophosphate-activated protein kinase), total and phospho-ACC (1:2,000 
dilution) (Ser79) (acetyl-CoA carboxylase), total and phospho-eEF2 (1:25,000 
dilution) (Thr56), total and phospho-4E-BP1 (1:1,000 dilution) (Thr37/46), and 
total and phospho-Akt (1:1,000 dilution) (Ser473). All primary antibodies used 
were purchased from Cell Signaling (Boston, MA), unless stated otherwise. Anti-
rabbit IgG, HRP-linked secondary antibody was also purchased from Cell 
Signaling (1:2,000 dilution) (Boston, MA).  
Nucleotide analysis. Adenosine 5'-monophosphate (AMP) and adenosine 
5'-triphosphate (ATP) were determined by HPLC analysis as described in a 
technical note CN-039 by Phenomenex (Torrance, CA). Briefly, frozen 
gastrocnemius muscle was ground under liquid nitrogen and 50 mg of sample 
was combined with 1 ml of MeOH in water (25:75) and vortexed. This sample 
was centrifuged at 10,000 RPM at 4 °C for 5 min and the supernatant extracted. 
The supernatant was dried and then reconstituted in phosphate buffered saline 
(PBS). The sample was then passed through a Strata X-AW 33u Polymeric 
Weak Anion Solid Phase Extraction Sorbent (Phenomenex, Torrance, CA). Ten 
microliter aliquots of the final muscle extract were injected onto the HPLC using a 
Phenomenex Gemini 5u C18 110A Column 150 x 4.6 mm with temperature set at 
°25. A single mobile phase was used at a flow rate of 1 ml / min with 25% 
acetonitrile / 10mM KH2PO4 pH 7.0 (pH was adjusted with potassium hydroxide 
(KOH) / 5mM tetrabutylammonium chloride (TBAC). Nucleotide peaks were 
measured by UV detection at wavelength 260 nm. Peaks were identified by 
comparison with external standards (Sigma-Aldrich, St. Louis, MO).   
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Statistical analysis. All data were analyzed by SPSS (version 19) 
statistical software package for Windows. Experiment 1 data was analyzed using 
a one-way ANOVA, with the postprandial times and dietary treatments as the 
independent variables. When a significant overall effect was detected, 
differences among individual means were assessed using LSD post hoc test. 
Experiment 2 data was analyzed using a two-way ANOVA to assess main effects 
for gavage treatments (Leu80, CHO1.0, and Sham) and time (20, 45, and 120 
min post-gavage) as the independent variables. When a significant main effect 
was detected, differences among treatment groups were assessed with LSD 
post-hoc test. The level of significance was set at P < 0.05 for all analysis. Data 
are reported as mean ± S.E.   
 
RESULTS 
Experiment 1 evaluated the potential for supplemental Leu or 
carbohydrates to extend the peak MPS response after a meal, and if there was a 
dose response. Consistent with previous research (29), experiment 1 showed 
that MPS increased at 90 min after a 4 g control meal but returned to baseline by 
180 min post-meal (Sham). Leu270 or CHO2.6 supplements given at 135 min 
after the meal maintained MPS at rates similar to peak values at 90 min post-
meal (Fig. 5.1a). Supplementation with Leu80 or CHO1.0 maintained MPS above 
baseline (ie Sham group, P < 0.05) but lower than the 90 min post-meal peak 
value (P < 0.05) (Fig. 5.1a).  
Phosphorylation of AMPKα (Thr172) and ACC (Ser79) (Table 5.1) and the 
nucleotide ratio of AMP / ATP (Fig. 5.2a) were measured as indicators of cellular 
energy status. At 90 min after the control meal, phosphorylation of muscle 
AMPKα (P = 0.15) and ACC (P < 0.05) tended to decline reflecting increased 
energy availability and then increased at 180 min consistent with declining 
energy availability (P < 0.05). The Leu270 supplement reduced phospho-AMPKα 
and ACC and reduced the AMP / ATP ratio relative to the 90 min time-point. The 
Leu80 supplement suppressed phospho-ACC (P < 0.05) but phospho-AMPKα 
and AMP / ATP were not different from the 180 min sham control. Both 
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carbohydrate supplements, CHO2.6 and CHO1.0, maintained reduced phospho-
AMPKα relative to the 90 min time-point, with the greatest effect coming from the 
CHO2.6 supplement. Similar results were seen for both carbohydrate 
supplements for phospho-ACC and AMP / ATP.   
Phosphorylation of eEF2 (Thr56) was measured as a biomarker of 
translation elongation (Table 5.1). After the meal, eEF2 phosphorylation tended 
to decrease from 0 to 90 min (P = 0.15) consistent with stimulation of MPS, but 
increased at 180 min post-meal (Sham control) (P < 0.05), suggesting inhibition 
of elongation. The Leu270 supplement reduced eEF2 phosphorylation at 180 min 
relative to Sham control (P < 0.05), while the Leu80 supplement elicited an 
intermediate response that was not statistically different from with Sham or 90 
min peak values. Both CHO2.6 and CHO1.0 supplements reduced eEF2 
phosphorylation at 180 min relative to the Sham control (P < 0.05).  
Phosphorylation of 4E-BP1 (Thr37/46) was measured as a biomarker of 
translation initiation and a specific indicator of mammalian target of rapamycin 
(mTORC1) signaling (Table 5.1). Consistent with previous findings (29), relative 
phosphorylation of 4E-BP1 (Thr37/46) in muscle increased at 90 min (P < 0.05) 
and remained elevated at 180 min (sham control) compared with food deprived 
rats (time 0) (P < 0.05) with no additional activation after either the Leu or CHO 
treatments.  
Plasma insulin rose at 90 min post-meal and returned to food-deprived 
(time 0) values at 180 min (Sham) (Table 5.1). The CHO2.6 and CHO1.0 
supplements restored insulin to 90 min peak insulin values, while the Leu270 and 
Leu80 supplements had no effect on insulin relative to sham control. 
Phosphorylation of Akt (Ser473) was measured as an indicator of insulin 
signaling but no differences in Akt activation were detected among the groups 
(Table 5.1). 
As expected, plasma Leu and EAAs increased 90 min after the meal and 
remained elevated at 180 min (Table 5.2). The Leu270 supplement elevated 
plasma Leu; however, the supplement also depressed plasma isoleucine and 
valine below sham values, with no effect on other amino acids relative to sham 
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(Table 5.2). The Leu80 supplement elevated plasma Leu, isoleucine, and valine 
above sham control, with no effect on other amino acids relative to sham. Lastly, 
both carbohydrate supplements had no effect on plasma amino acids relative to 
sham.  
Experiment 2 evaluated effects of Leu80 and CHO1.0 supplements on 
MPS, energy status, and signaling outcomes at multiple time-points post-gavage. 
Both Leu80 and CHO1.0 treatments maintained MPS above sham values (ie. 
180 min sham control) at 20 and 45 min post-gavage (two-way ANOVA P < 0.05 
main effects for treatment and time, with no interaction P = 0.16) (Fig. 5.1b) but 
MPS declined to baseline values by 120 min post-gavage (Fig. 5.1b).  
The CHO1.0 treatment tended to suppress phospho-AMPKα (P = 0.13) 
(Table 5.3) and AMP / ATP (P = 0.09) (Fig. 5.2b) relative to Sham control by 20 
min post gavage, but significantly reduced phospho-AMPKα (two-way ANOVA P 
< 0.05 main effect for time, with a significant interaction), phospho-ACC (two-way 
ANOVA P < 0.05 main effect for treatment), and AMP / ATP (two-way ANOVA P 
< 0.05 main effect for treatment) by 45 min post-gavage. All of these values were 
similar to Sham controls at 120 min.  
The Leu80 supplement suppressed phospho-AMPKα (P < 0.05), AMP / 
ATP (P < 0.05), and tended to decrease phospho-ACC (P = 0.12) relative to 
sham control at 20 min post-gavage (P < 0.05); however, phospho-AMPKα, and 
AMP / ATP returned to sham levels at 45 and 120 min post-gavage for the Leu80 
treatment. Phospho-ACC remained depressed 45 min post-gavage for the Leu80 
treatment relative to sham control (P < 0.05) and returned to sham values 120 
min post-gavage consistent with a temporal sequence for energy signaling.  
 Phosphorylation of eEF2 (Thr56) was lower at 20 and 45 min post-gavage 
after the CHO1.0 treatment relative to sham, but rose to sham values 120 min 
post-gavage (two-way ANOVA P < 0.05 main effect for treatment) (Table 5.3). 
While the Leu80 treatment transiently decreased phospho-eEF2 at 20 min post-
gavage relative to sham control but phosphorylation increased by 45 min.  
There was a trend for the CHO1.0 supplement to increase 
phosphorylation of 4E-BP1 (Thr37/46) relative to the Leu80 treatment and sham 
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control (two-way ANOVA P < 0.05 main effect for treatment) however, post hoc 
analysis did not detect significant differences among treatments, within time-
points (Table 5.3).  
Plasma insulin was increased by the CHO1.0 supplement 45 and 120 min 
post-gavage, relative to Sham control (two-way ANOVA P < 0.05 main effect for 
treatment) (Table 5.3). While the Leu80 supplement had no effect on plasma 
insulin relative to Sham control. No differences were found for phosphorylation of 
Akt (Ser473) (Table 5.3).  
As anticipated, the Leu80 supplement increased plasma BCAA (Leu, 
isoleucine, and valine) above sham control at 20 and 45 min post-gavage, but 
returned to sham control values at 120 min post-gavage (two-way ANOVA P < 
0.05 main effects for treatment and time, with a significant interaction). While the 
CHO1.0 supplement had no effect on plasma BCAA relative to sham control 
(Table 5.4). Plasma lysine and methionine peaked 20 min post-gavage (two-way 
ANOVA P < 0.05 main effect for time), but there were no group differences. 
There was an overall main effect for plasma threonine to be decreased by the 
Leu80 treatment, relative to the CHO1.0 treatment and Sham control (two-way 
ANOVA P < 0.05 main effects for treatment and time, with no interaction); 
however, post hoc analysis did not detect differences among treatments, within 
time-points (Table 5.4).   
 
DISCUSSION 
Consistent with previous findings (29), this study demonstrates that Leu or 
carbohydrate supplements provided ~2 h after a meal can extend the 
postprandial anabolic period of MPS (Fig. 5.1). Further, the incongruity between 
MPS and mTORC1 signaling reported in both humans (7) and rats (25) ~3 h after 
a meal is associated with activation of AMPK and reduced translation elongation 
activity (Table 5.1 and Table 5.3) suggesting that the duration of the anabolic 
period after a meal relates, at least in part, to muscle energy status. The current 
research extends previous findings by further characterizing dose and time-
dependent responses to Leu or carbohydrate supplements.  
  94 
MPS peaked 90 min after the meal and declined by 180 min (Fig. 5.1a). 
While supplementation with Leu270 or CHO2.6 at 135 min after the meal 
increased MPS at 180 min above Sham controls and equal to the control group 
at 90 min (Fig. 5.1a). Supplementation with Leu80 or CHO1.0 at 135 min post-
meal increased MPS at 180 min above Sham rats; however, MPS was still lower 
than the 90 min peak value (Fig. 5.1a). Lastly, the ability of Leu80 and CHO1.0 to 
extend post-prandial MPS occurred 20-45 min after administration, but returned 
to sham values by 120 min post gavage (Fig. 5.1b).  
Results showed an inverse association with measures of energy status 
(phospho-AMPKα, ACC, and AMP / ATP) and MPS. Leu and carbohydrates are 
both energy substrates in skeletal muscle but would be expected to have 
different impacts on cellular energy and signaling. Yet, this research 
demonstrated that both substrates were effective at increasing energy and 
extending post-prandial MPS. When considering that CHO2.63 and CHO1.0 
supplements provided ~10-15 and 5-6 times more energy than Leu270 and 
Leu80 supplements, respectively, it is surprising that similar energetic responses 
(phospho-AMPKα, ACC, and AMP / ATP) were found in skeletal muscle. These 
findings suggest that the BCAA are a more efficient source of energy for 
maintaining MPS than carbohydrates. Indeed, while carbohydrates are used as 
an energy source in tissues and cells throughout the body, the BCAA have 
unique and preferential utilization in skeletal muscles (24, 26).  
  Catabolism of most amino acids occurs in the liver facilitating disposal of 
the amino-nitrogen group in the urea cycle. However, the liver lacks the 
branched-chain aminotransferase (BCAT) enzyme required to initiate BCAA 
degradation. After a meal, amino acid degradation accelerates in the liver and 
enterocytes, blunting post-prandial swings in amino acid concentrations. Nearly 
99% of glutamine, 75% of threonine and 50% of phenylalanine are lost to 
degradation or protein synthesis on the first pass through the visceral bed (12, 
21). However, absence of the BCAT in liver results in over 70% of Leu and the 
other two BCAA, valine and isoleucine, reaching systemic circulation. This is a 
striking metabolic difference for these amino acids which becomes even more 
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remarkable with the realization that the three BCAA account for over 20% of total 
dietary protein.  
Increased BCAA oxidation is triggered by transamination of Leu to 
ketoisocaproate (KIC), mediated by BCAT. Increased KIC levels in skeletal 
muscle have been shown to increase oxidation of all three BCAA (Leu isoleucine, 
and valine) by allosteric activation of branched-chain α-keto-acid dehydrogenase 
(BCKDH) – which is responsible for the non-reversible oxidation of all three 
BCAA into their respective keto acids (1, 14). While all three keto-acids of Leu, 
isoleucine, and valine can increase BCKDH activity, research shows that KIC is a 
much stronger stimulus (1). In support of the hypothesis that Leu provided ATP 
to muscle by increasing BCAA oxidation, Leu270 reduced isoleucine and valine 
concentrations by ~50%, while other plasma EAAs remained unchanged relative 
to sham control (Table 5.2).  
Beyond increased BCAA oxidation in skeletal muscle, Leu can also 
provide energy by providing substrate for synthesis of glutamine and alanine, 
thereby facilitating the glucose-alanine cycle (2, 19). Previous research has also 
demonstrated that higher protein diets increase the “flux” of glucose into skeletal 
muscle, without increasing plasma glucose concentrations, suggesting that 
protein makes muscle more efficient at "re-cycling" existing glucose (8). The 
collective result of Leu metabolism in skeletal muscle is increased TCA cycle 
intermediates (anaplerosis) (28), increased ATP production (11), and increased 
MPS (3).  
The ability of the Leu supplements to decrease AMPKα phosphorylation 
(Table 5.1) is consistent with the work of Du et al. (11), who showed that Leu 
treatment in C2C12 myoblast cells resulted in a 36% decrease in the AMP / ATP 
ratio, a 28% reduction in phospho-AMPKα, and a 43% reduction in AMPK 
activity.  
One apparent deviation between the association of energy status and 
MPS, was that the while the Leu80 supplement increased MPS for 45 min, it was 
only able to depress phospho-AMPKα, and AMP / ATP for 20 min. However, 
phospho-ACC remained depressed 45 min after the Leu80 gavage, suggesting 
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that AMPKα activity was not peaked, yet; perhaps, explaining why MPS still 
remained elevated 45 min after the Leu80 supplement (Fig. 5.1a), in spite of 
elevated AMPKα at that time-point. Corresponding with the drop in MPS, 
Phospho-ACC rose to sham values 120 min after the Leu80 gavage, indicating 
that AMPKα had reached its peak activity.  
It is interesting that the Leu80 supplement, which contained a balance 
BCAA formula, was not as effective as Leu270 at decreasing phospho-AMPKα 
(Table 5.1). While all three keto-acids of Leu, isoleucine, and valine can increase 
BCKDH activity, research shows that the Leu metabolite KIC is the strongest 
stimulus (1). Thus, in the present experiment, Leu270 likely served as a greater 
stimulus for BCAA oxidation, and therefore, ATP production, than the more 
balanced Leu80 formula. This dose effect of Leu supplements to improve cellular 
energy could also explain why cellular energy decreased 180 min post meal, 
despite the fact that plasma BCAA were approximately 50% higher than baseline 
values (Table 5.2). Collectively, these findings suggest that robust increases in 
plasma BCAA are required to maximally stimulate these energetic pathways, and 
provide adequate energy to maintain MPS (Fig. 5.3).  
As with previous findings (29), phosphorylation of eEF2 was associated 
with MPS responses, indicating that translation elongation becomes limiting in 
the postprandial state. Proud and colleagues (9, 20) have shown that inhibition of 
eEF2 and protein synthesis in response to mild energy deficits, is associated with 
activation of AMPKα, which stimulates the regulatory kinase eEF2K to 
subsequently phosphorylate (inhibit) eEF2. Likewise, the results of this 
experiment suggests that temporal changes in skeletal muscle energy state 
following meal feeding influence the period of muscle anabolism, particularly 
through inhibition of translation elongation. Further, the energy status of muscle 
and period of muscle anabolism can be enhanced by post-meal nutrition 
supplements.  
MPS declined 180 min post-meal (sham) in spite of continued elevations 
in phosphorylation of mTORC1 signaling target 4E-BP1 (Table 5.1) and plasma 
amino acids (Table 5.2). Likewise, insulin does not appear to be a critical factor 
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in extending MPS (Table 5.1 and Table 5.3). Plasma insulin rose at 90 min post-
meal and returned to food-deprived (time 0) values at 180 min (Sham) (Table 
5.1). The CHO2.6 and CHO1.0 supplements restored insulin to 90 min peak 
insulin values. Furthermore, plasma insulin was increased by the CHO1.0 
supplement 45 and 120 min post-gavage, relative to Sham control (Table 5.3). 
However, Leu270 and Leu80 supplements had no effect on insulin relative to 
sham control, at any time-point (Table 5.3). 
It is noteworthy that both Leu270 and Leu80 supplements had no effect on 
plasma insulin, as previous research has shown that Leu increases plasma 
insulin when given in the fasted state (5). In the present scenario, where Leu is 
administrated post meal, it is possible that the test meal depleted insulin vesicle 
storage and that Leu has no direct effect on protein kinase B (PKB) stimulation of 
insulin synthesis. Regardless, it appears that Leu270 and Leu80 supplements 
given after a meal are able to extend protein synthesis without significantly 
elevating plasma insulin.  
 Previous research has demonstrated that administering carbohydrates in 
the fasted state is ineffective at elevating MPS (4). Thus, the finding in this 
experiment that consumption of carbohydrates alone is sufficient to increase 
MPS is a novelty. The likely explanation for this discrepancy is that in these 
experiments, carbohydrates are administered shortly after consumption of a 
mixed meal. In this scenario, amino acids are still elevated and translation 
initiation has already been triggered. The “system” is simply limited by energy; 
thus, administration of an energy source (carbohydrates) appears to be 
satisfactory to prolong MPS.  
In summary, intake of a Leu or carbohydrate supplement ~2 h after 
consumption of a complete meal can extend of the postprandial rise in MPS, and 
this response is associated with enhanced energy and translation elongation 
activity. However, the novel finding of this research is that the extent to which 
Leu or carbohydrate supplements are able to enhance energy status and prolong 
the period of muscle anabolism, are dose and time-dependent. In practical terms, 
this would suggest that a “snack” between meals would extend the postprandial 
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anabolic period. But this effect is transient, and another meal must be consumed 
shortly thereafter to prolong muscle anabolism. Improved understanding of 
factors that regulate the duration of MPS may have implications for maintenance 
of lean tissue during weight loss or aging, for treatment of patients suffering 
trauma or prolonged bed rest, as well as for acceleration of muscle development 
in athletes. As such, the roles of eEF2 and AMPK in regulation of postprandial 
MPS warrant further investigation.  
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FIGURES AND TABLES 
 
 
 
Fig. 5.1. Postprandial changes for muscle protein synthesis (MPS). Values are mean ± S.E.M, n 
= 5-8 per group. Rats were fed a 4 g breakfast meal containing 20% whey protein, and and 
received supplements at 135 min post-meal. Panel A (experiment 1). Rats were gavaged with 
water (Sham), 270 mg of leucine (Leu270), 80 mg leucine, 40 mg isoleucine, and 40 mg valine 
(Leu80), 2.63 g carbohydrates (CHO2.6), or 1 g carbohydrates (CHO1.0). Means not sharing a 
common letter are different (One-way ANOVA P < 0.05).  Panel B (experiment 2). Rats were 
gavaged with water (Sham), 80 mg leucine, 40 mg isoleucine, and 40 mg valine (Leu80), or 1 g 
carbohydrates (CHO1.0). Means not sharing a common letter are different within time-points (P < 
0.05). Two-way ANOVA P < 0.05 indicated significant main effects for treatment and time, with no 
interaction (P = 0.160).   
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Fig. 5.2. Postprandial changes for nucleotide ratios of AMP / ATP (adenosine 5′-monophosphate / 
adenosine 5′-triphosphate). Values are mean ± S.E.M, n = 5-8 per group. Rats were fed a 4 g 
breakfast meal containing 20% whey protein, and gavaged 135 min post-meal. Panel A 
(experiment 1). Rats were gavaged with water (Sham), 270 mg of leucine (Leu270), 80 mg 
leucine, 40 mg isoleucine, and 40 mg valine (Leu80), 2.63 g carbohydrates (CHO2.6), or 1 g 
carbohydrates (CHO1.0). Means not sharing a common letter are different (One-way ANOVA P 
<0.05).  Panel B (experiment 2). Rats were gavaged with water (Sham), 80 mg leucine, 40 mg 
isoleucine, and 40 mg valine (Leu80), or 1 g carbohydrates (CHO1.0). Means not sharing a 
common letter are different within time-points (P <0.05). Two-way ANOVA P <0.05 indicated 
significant main effect for treatment.  
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Fig. 5.3. Leucine (Leu) metabolism and regulation of muscle protein synthesis (MPS). Leu is able 
to pass through the liver without being oxidized due to the lack of BCAT (branched-chain amino- 
acid transferase). In muscle, Leu activates the mTOR (mammalian target of rapamycin) pathway, 
resulting in improved translation initiation and MPS. The Leu metabolite KIC (keto-isocaproate) 
induces alosteric activation of BCKDH (branched-chain keto acid dehydrogenase), resulting in 
increased oxidation of the BCAA (branched-chain amino-acids). Increased energy from BCAA 
oxidation (or a decrease in AMP:ATP ratio, adenosine 5′-monophosphate / adenosine 5′-
triphosphate) reduces activity of AMPK (AMP activated protein kinase) attenuating AMPK 
induced activation of eEF2K (eukaryotic elongation factor 2 kinase), the regulatory kinase of 
eEF2. TCA (tricarboxylic acid cycle); ETC (electron transport chain).  
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Table 5.1. Post-meal signaling1 and plasma insulin2 results for experiment one3    
_________________________________________________________________________________________ 
Time4         
_________________________________________________________________________________________ 
 
   AMPK ACC eEF2 4E-BP1 Akt Insulin 
0  3.2±0.2ab 4.8±0.5a 4.1±0.1ab 1.3±0.2b 2.3±0.5 43±8.7ab 
90  1.8±0.2b 2.0±0.3b 2.8±0.3b 2.5±0.4a 2.1±0.7 53±5.8a 
180 
Sham5  4.6±0.8a 4.0±0.7a 5.1±1.0a 3.2±0.5a 1.7±0.2 39±0.4b 
Leu2706  1.9±0.5cb 2.0±0.7b 2.4±0.2b 3.3±0.6a 2.1±0.4 41±1.2ab 
Leu807  4.8±1.1a  2.4±0.5b 3.9±0.8ab 3.1±0.5a 1.7±0.4 40±3.4b 
CHO2.68  1.2±0.3c 1.4±0.4b 2.3±0.1b 4.0±0.6a 2.3±0.4 47±3.2ab 
CHO1.09  2.6±0.4b 1.7±0.3b 2.7±0.5b 3.9±0.5a 2.7±0.6 51±3.3ab 
_________________________________________________________________________________________ 
1Western blot results indicate relative changes in phosphorylation of adenosine monophosphate-activated 
protein kinase alpha (phospho-AMPKα (Thr172) / total AMPKα), acetyl-CoA carboxylase (phospho-ACC 
(Ser79) / total ACC), eukaryotic elongation factor 2 (phospho-eEF2 (Thr56) / total eEF2), eIF4E binding protein-
1 (phospho-4E-BP1 (Thr37/46) / total 4E-BP1), and phospho-Akt (Ser473) / total Akt. 
2Plasma insulin expressed as pmol/L.  
3Values are means ± S.E.M, n = 5-8 per group. Means not sharing a common letter are different (One-way 
ANOVA P < 0.05).  
4Time expressed as min post-meal.  
5Control animals were fed a 4 g breakfast meal containing 20% whey protein, and administered a sham (water) 
gavage. 
6Rats were gavaged with 270 mg of leucine (Leu270). 
7Rats were gavaged with 80 mg leucine, 40 mg isoleucine, and 40 mg valine (Leu80). 
8Rats were gavaged with 2.63 g carbohydrates (CHO2.6). 
9Rats were gavaged with 1 g carbohydrates (CHO1.0)  
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Table 5.2. Post-meal plasma amino acid responses for experiment one1, 2 
_________________________________________________________________________________________ 
Time3         
_________________________________________________________________________________________ 
   Leu Ile Val Lys Met Thr  
0  163±11d 123±9b 192±15c 743±78b 80±6b 726±36b 
90  299±42c 244±36a 327±44b 1016±98a 122±13a  955±85a 
180  
Sham4  220±9cd 163±7ab 256±10bc 797±33ab 98±7ab 780±28ab 
Leu2705  1375±113a111±11b 172±16c 925±68a 88±5b 743±47b 
Leu806  523±51b  301±28a 591±40a 767±34b 73±5b 640±71b 
CHO2.67  224±36cd 128±18b 200±37c 623±117b 92±11b 737±51b 
CHO1.08  188±22d 154±20b 231±27c 779±80b 88±13b 747±42b 
_________________________________________________________________________________________ 
1Plasma amino acids expressed as µmol/L. 
2Values are means ± S.E.M, n = 5-8 per group. Means not sharing a common letter are different (One-way 
ANOVA P < 0.05).  
3Time expressed as min post-meal.  
4Control animals were fed a 4 g breakfast meal containing 20% whey protein, and administered a sham (water) 
gavage.  
5Rats were gavaged with 270 mg of leucine (Leu270).  
6Rats were gavaged with 80 mg leucine, 40 mg isoleucine, and 40 mg valine (Leu80). 
7Rats were gavaged with 2.63 g carbohydrates (CHO2.6). 
8Rats were gavaged with 1 g carbohydrates (CHO1.0).
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Table 5.3. Post-gavage signaling1 and plasma insulin2 results for experiment two3    
_________________________________________________________________________________________ 
Time4         
_________________________________________________________________________________________ 
Sham5  AMPK#+ ACC* eEF2*  4E-BP1* Akt Insulin* 
20  4.4±0.3a 3.6±0.6 4.9±0.2a 2.8±0.2 1.8±0.3 42±0.9 
45  4.6±0.7 a 4.0±0.6a 5.1±1.0a 3.2±0.5 1.7±0.2 39±0.4b 
120  4.4±0.8 3.8±0.7 4.1±0.6 2.9±0.2 1.8±0.2 35±0.4b 
Leu806 
20  1.8±0.3b 2.2±0.5 2.8±0.7b 3.0±0.4 2.6±0.4 41±1.5 
45  4.8±1.1a 2.5±0.5b 3.9±0.7ab 3.0±0.5 1.7±0.4 40±3.4b 
120  4.8±0.8 3.4±0.8 4.4±0.6 3.4±0.5 2.2±0.3 37±4.5ab 
CHO1.07 
20  2.8±0.3ab 2.7±0.4 2.8±0.6b 3.8±0.6 2.2±0.4 47±2.3 
45  2.6±0.4b 1.7±0.3b 2.7±0.5b 3.9±0.5 2.7±0.6 51±3.3a 
120  5.0±0.4 2.5±0.7 3.6±0.5 4.2±0.5 2.7±0.6 45±0.6a 
_________________________________________________________________________________________ 
1Western blot results indicate relative changes in phosphorylation of adenosine monophosphate-activated 
protein kinase alpha (phospho-AMPKα (Thr172) / total AMPKα), acetyl-CoA carboxylase (phospho-ACC 
(Ser79) / total ACC), eukaryotic elongation factor 2 (phospho-eEF2 (Thr56) / total eEF2), eIF4E binding 
protein-1 (phospho-4E-BP1 (Thr37/46) / total 4E-BP1), and phospho-Akt (Ser473) / total Akt.  
2Plasma insulin expressed as pmol/L.  
3Values are means ± S.E.M, n = 5-8 per group. Means not sharing a common letter are different within time-
points (P < 0.05). Two-way ANOVA P < 0.05 indicated significant main effects for treatment (*), time (#), and 
significant interaction (+).  
4Time expressed as min post-gavage.  
5Control animals were fed a 4 g breakfast meal containing 20% whey protein, and administered a sham 
(water) gavage at indicated times. 
6Rats were gavaged with 80 mg leucine, 40 mg isoleucine, and 40 mg valine (Leu80). 
7Rats were gavaged with 1 g carbohydrates (CHO1.0). 
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Table 5.4. Post-gavage plasma amino acid responses for experiment two1, 2  
_________________________________________________________________________________________ 
Time3         
_________________________________________________________________________________________ 
Sham4  Leu*#+ Ile*#+ Val*#  Lys# Met# Thr*#  
20  258±5b 192±8b 301±15b 868±68 118±10 882±32 
45  220±8b 163±6b 255±8b 797±29 98±6 780±23 
120  173±5ab 127±4 204±7b 729±25 79±5 673±19 
Leu805 
20  744±83a 482±52a 703±72a 919±56 107±9 721±41 
45  523±51a 301±28a 591±40a 767±34 73±4 639±70 
120  281±22a 174±15 444±34a 715±49 66±6 559±87 
CHO1.06 
20  247±13b 200±7b 300±13b 894±34 108±6 722±26 
45  188±22b 153±20b 230±26b 778±80 88±13 746±42 
120  170±7b 134±8 205±10b 783±50 84±7 708±76  
_________________________________________________________________________________________ 
1Plasma amino acids expressed as µmol/L. 
2Values are means ± S.E.M, n = 5-8 per group. Means not sharing a common letter are different within time-
points (P < 0.05). Two-way ANOVA P < 0.05 indicated significant main effects for treatment (*), time (#), and 
significant interaction (+).  
3Time expressed as min post-gavage.  
4Control animals were fed a 4 g breakfast meal containing 20% whey protein, and administered a sham 
(water) gavage at indicated times. 
5Rats were gavaged with 80 mg leucine, 40 mg isoleucine, and 40 mg valine (Leu80).  
6Rats were gavaged with 1 g carbohydrates (CHO1.0). 
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CHAPTER VI:  
SUMMARY AND SPECULATIONS 
 
DIETARY LEUCINE DETERMINES MUSCLE ANABOLISM 
  Studies have demonstrated that leucine (Leu) is a potent stimulator of 
mammalian target of rapamycin (mTORC1) kinase activity, resulting in improved 
translation initiation and muscle protein synthesis (MPS) (2, 8). However, most of 
this research has been done with purified Leu formulas, or in vitro experiments, 
and is untested with whole foods using in vivo models. Accordingly, this 
dissertation sought to better define the role of dietary Leu in regulation of skeletal 
muscle protein balance using whole food feeding models.  
Research from this dissertation demonstrates that the peak activation of 
MPS following a small breakfast meal is proportional to the Leu content of a meal 
and its ability to elevate plasma Leu. Furthermore, consuming higher Leu diets 
results in greater increases in muscle mass over ~3 months of meal feeding. 
Healthy adult rats were fed three complete meals daily with identical 
macronutrient compositions (16% of energy from protein, 54% carbohydrates, 
30% fats), which only differed in the source of protein (Chapter II). Four proteins 
(wheat gluten, soy isolate, egg white, and whey protein isolate) were selected to 
provide a range of Leu concentrations from 6.8% to 10.9% (w/w). Results 
demonstrated that consumption of animal proteins with higher Leu contents 
(whey and egg) increased MPS, mTORC1 signaling, and plasma Leu; while 
consumption of plant proteins (wheat and soy) were unable to increase MPS or 
plasma Leu. Moreover, supplementing wheat with Leu to match the Leu content 
of the meal to that of whey also equalized rates of MPS. To my knowledge, this is 
the first study to show the significance of Leu as a factor of protein quality within 
meals containing complete macronutrient and fiber mixtures. These findings are 
consistent with the concept of a “minimum threshold” for Leu to stimulate mTOR 
and MPS (2).  
Additional research from this dissertation showed minimal changes in 
muscle protein degradation (MPD) pathways, regardless of the Leu content of 
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the diets. Suggesting that MPS is the primary determinant of protein turnover in 
healthy adult rat feeding models.  
Previous MPD research has focused on regulation of the ATP-dependent 
ubiquitin-proteosome-proteolytic pathway, which is the primary mode of 
intracellular protein degradation (6). While there is evidence that the ubiquitin-
proteosome pathway may be a major factor in protein turnover during aging and 
in states of muscle wasting (1), nearly all research on the effects of protein or 
amino acid supplementation on protein turnover has focused on MPS. Therefore, 
this research extends the current understanding of how nutrition impacts MPD. 
Chapter III examined ubiquitin-proteosome outcomes after feeding rats a range 
of proteins varying in Leu density (whey, egg, and wheat) over a period of 11 
weeks. The primary finding was that total PSMA2 (a portion of the outer ring of 
the 20S proteasome) significantly decreased in rats fed egg and whey compared 
to animals fed wheat, suggesting decreased total proteasome degradative 
capacity in rats consuming higher Leu diets. However, there was no effect of diet 
treatment on any of the regulatory ubiquitin ligases. These results suggest that 
protein quality within accepted dietary ranges has minimal regulatory effects on 
MPD in healthy adult rats. Thus, the changes in muscle mass observed overtime 
in this dissertation are likely due to the differences in MPS, rather than MPD.  
  After an overnight fast, muscle is in a state of catabolism, and nutrients 
must be consumed to halt this response. Indeed, research has demonstrated that 
the breakfast meal is an important determinant of metabolism and satiety 
outcomes for the remainder of the day, with higher protein, lower carbohydrate 
breakfast meals improving these outcomes (5, 7). However, Americans typically 
consume small breakfast meals (20% of daily energy) with a mixture of 
macronutrients that are limited in protein quantity (16% of energy from protein, 
54% carbohydrates, 30% fats). Accordingly, the research presented in this 
dissertation was designed to mimic the typical American breakfast meal, to 
determine how the quality of proteins determines muscle anabolism and muscle 
mass outcomes.  
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  Results from this dissertation showed that the Leu density of proteins is an 
important determinant of protein quality, and determines the post meal anabolic 
response. Thus, when consuming a small breakfast meal with limited protein 
quantity, the quality of the protein (Leu content) becomes absolutely critical. In 
practical terms, this means that consuming plant proteins such as a bagel and 
orange juice that are limited in both protein quantity and quality for breakfast is 
ineffective at halting muscle catabolism. Rather, protein sources that are rich in 
Leu, such as animal proteins including milk and eggs, must be consumed to 
begin muscle repair.  
 These results call into question current recommendations of protein 
quality. For the proteins used in this study only the wheat glutens lysine content 
was below the National Research Council (NRC) requirement for the adult rat 
(10). This specific requirement was corrected by supplementing the wheat gluten 
diet with lysine to the level of the concentration in whey protein. All other EAA 
exceeded NRC guidelines. The unique regulatory role of Leu may in part explain 
the inconsistencies in comparison of optimal needs for Leu compared with 
current measures of minimum protein requirements for nitrogen balance or 
indispensable amino acid oxidation (IAAO) measurements. These standard 
measurements for protein requirement interpret postprandial increases in plasma 
amino acids as inefficient and excessive protein intake. While increased amino 
acid oxidation may reflect reduced efficiency of nitrogen retention of dietary 
protein and may provide an accurate representation of minimum requirements for 
an EAA such as lysine with no known metabolic signaling or regulatory roles, the 
extrapolation that protein intakes above the minimum amount for short-term 
nitrogen balance are physiologically meaningless is not consistent with the 
regulatory role of Leu in MPS.    
 
CELLULAR ENERGY DETERMINES MUSCLE ANABOLISM 
Chapter IV and V investigated the postprandial duration of MPS and 
whether a second dose of nutritional supplements could extend the duration of 
peak MPS, as well as the mechanisms underlying these responses. Results 
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showed that MPS increased 90 min post meal, but returned to fasted values 180 
min post meal, in spite of maintained elevations in mTORC1 signaling and 
plasma Leu. Rather, an inverse association was found between MPS, markers of 
translation elongation (eukaryotic elongation factor 2 (eEF2)), and cellular energy 
(AMP/ATP, adenosine monophosphate-activated protein kinase (AMPK), and 
acetyl CoA carboxylase (ACC)). However, supplementation with a second dose 
of Leu or carbohydrates 135 min post meal was able to prevent the drop in 
cellular energy, translation elongation, and MPS in a dose and time-dependent 
manner.  
Leu and carbohydrates are both energy substrates in skeletal muscle but 
would be expected to have different impacts on cellular energy and signaling. 
Yet, this research demonstrated that both substrates were effective at increasing 
energy and extending post-prandial MPS. When considering that the 
carbohydrate supplements provided ~10-15 and 5-6 times more energy than the 
Leu supplements, it is surprising that similar energetic responses (phospho-
AMPKα, ACC, and AMP / ATP) were found in skeletal muscle. These findings 
suggest that the BCAA are a more efficient source of energy for maintaining MPS 
than carbohydrates. Indeed, while carbohydrates are used as an energy source 
in tissues and cells throughout the body, previous research has shown that the 
BCAA have unique and preferential utilization in skeletal muscles (24, 26).  
To my knowledge, this is the first demonstration of limitations in translation 
elongation and cellular energy determining MPS outcomes, in a physiological 
feeding model. Muscle has a number of energy substrates to protect ATP levels 
(creatine-phosphate, lipids, glycogen, etc.); however, this research suggests that 
the metabolically costly process of MPS can exceed the muscles ability to 
maintain cellular energy.  
Proud and colleagues have shown inhibition of eEF2 and protein 
synthesis in response to mild energy deficits is associated with activation of 
AMPK, which stimulates the regulatory kinase eukaryotic elongation factor 2 
kinase (eEF2K) to subsequently phosphorylate (inhibit) eEF2 (9). The ability of 
AMPK to respond to changes in AMP/ATP – with AMP stimulating AMPK, and 
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ATP inhibiting it – allows this kinase to be an effective cellular energy sensor (4). 
Collectively, these results suggest that energy is a likely determinate of the 
duration of postprandial MPS, and that eEF2 is the regulatory step responding to 
energy status.  
Considering that protein turnover is a metabolically costly process, 
accounting for approximately one quarter of resting energy expenditure (11), it is 
logical that a cell would suppress protein synthesis activity during an energy 
deficit to preserve critical functions. Furthermore, when considering that 
translation elongation accounts for the majority (> 99%) of the energy used for 
polypeptide assembly (9), it appears logical that the cell would regulate 
translation elongation to protect energy status. These findings may also explain 
why consuming dietary proteins results in a greater thermic effect than either 
carbohydrates or fats, via stimulation of MPS (3).  
In practical terms, these results suggest that a “snack” between meals 
would extend the postprandial anabolic period. But this effect is transient, and 
another meal must be consumed shortly thereafter to prolong muscle anabolism. 
Improved understanding of factors that regulate the duration of MPS may have 
implications for maintenance of lean tissue during weight loss or aging, for 
treatment of patients suffering trauma or prolonged bed rest, as well as for 
acceleration of muscle development in athletes.  
 
CONCLUSION 
In conclusion, this dissertation has shown that the Leu content of dietary 
proteins is an important determinate of protein quality, and determines the post 
meal anabolic response and chronic changes in muscle mass. MPD outcomes 
were less responsive than MPS to the Leu content of dietary proteins. Thus, the 
changes in muscle mass observed overtime are likely due to the differences in 
MPS, rather than MPD. Results showed that Leu works as both an anabolic 
signal via stimulation of the mTORC1 pathway, and as an energy substrate for 
muscle, thereby providing ATP, and inhibiting AMPK, to support the metabolically 
costly process of MPS.  
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This dissertation demonstrates the importance of protein quality at the 
breakfast meal, where small meals with limited protein are typically consumed. In 
practical terms, this means that consuming plant proteins such as a bagel and 
orange juice for breakfast is ineffective at halting muscle catabolism. Rather, high 
quality animal proteins such as milk and eggs must be consumed to begin 
muscle repair.  
Protein synthesis is an oscillating process, increasing after consumption of 
food, and decreasing in fasting conditions. This research demonstrated that MPS 
declined 180 min after a complete meal, in spite of maintained elevations in 
mTORC1 signaling and plasma Leu. Rather, an inverse association was found 
between markers of translation elongation, cellular energy, and MPS outcomes. 
However, supplementation with a second dose of Leu or carbohydrates 135 min 
post meal was able to prevent the drop in cellular energy, translation elongation, 
and MPS in a dose and time-dependent manner. In practical terms, these results 
suggest that a “snack” between meals would extend the postprandial anabolic 
period. But this effect is transient, and another meal must be consumed shortly 
thereafter to prolong muscle anabolism.  
This research has implications for maintenance of muscle health and 
functionality. Future studies should seek to extend these results in differing 
populations such as in muscle wasting models, the elderly, and with exercise.  
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